Multifocal Choroidopathy Syndromes

Multifocal Choroidopathy Syndromes

No Results

No Results

processing….

This group of rare disorders involves a primary pathologic process occurring at or near the level of the retinal pigment epithelium (RPE) with or without photoreceptor outer segment and choriocapillaris involvement. Ultimately, the etiology is presumed to be either a vasculitic obstruction of the choriocapillaris with secondary infarction of the overlying RPE or, possibly, an immunologic response directed at the RPE itself. Many clinical features of these individual entities overlap, causing much confusion. Whether these conditions represent distinct entities or whether some may be parts of a spectrum of the same basic disease is still unknown.

Other conditions of choroiditis with overlying RPE involvement are not described in this article; yet, they are important to consider in the differential diagnosis of these more atypical choroiditides, such as tuberculosis, histoplasmosis, syphilis, posterior scleritis, reticulum cell sarcoma, lymphoid neoplasia, diffuse unilateral subacute neuroretinitis (DUSN), and Lyme disease, or the more common idiopathic syndromes, such as central serous retinochoroidopathy, sarcoidosis, Vogt-Koyanagi-Harada syndrome, and sympathetic ophthalmia.

Attempts at grouping these myriad disorders, especially by Gass, have resulted in inclusion of multiple evanescent white dot syndrome (MEWDS), acute idiopathic blind spot enlargement syndrome (AIBSES), acute macular neuroretinopathy (AMN), and multifocal choroiditis (MFC) or pseudo–presumed ocular histoplasmosis (pseudo-POHS) under the term acute zonal occult outer retinopathy (AZOOR). [1] This inclusion group arose primarily from the observation of a few case reports where 2 or 3 of these entities had coincident manifestation in the same patient. [2]

AZOOR is characterized by the following common clinical features: minimal initial ophthalmoscopic changes, followed later by signs of retinochoroidal degeneration, rapid reduction in one or more parameters of the visual field, photopsia, and abnormalities on electrophysiologic testing. [3]

More recently, AIBSES has been characterized to have sufficiently unique clinical features, such that, despite some similarities to MEWDS, treating it as a distinct and separate entity may be wise. [4, 5, 6, 7, 8] AMN, a bilateral condition affecting otherwise healthy young adults, appears to involve a pathologic process occurring more in the middle and outer retinal layers rather than in the RPE and choriocapillaris. [9] As such, both AIBSES and AMN will not be discussed in this article.

There remains the conviction that the aforementioned entities are sufficiently distinct as to preclude any effective single inclusion group. [10] In the absence of any significant histopathologic and serologic findings, these conditions not only continue to present a problem as far as classification, but also remain poorly understood with regards to etiology or pathogenesis. The discussion of the various multifocal choroidopathy syndromes in this article will consider each entity separately and, in so doing, will avoid the thorny issue of endorsing any one classification.

Since the initial description of the disease by Nozik and Dorsch in 1973, hundreds of patients have been reported in the literature with multifocal choroiditis and panuveitis (MCP). [11] As mentioned earlier, many investigators have lately suspected that MCP is one and the same with several other disorders, all representing various stages of the same basic clinical entity (ie, AZOOR). With further follow-up of some of these patients, hopefully, this spectrum of clinical manifestations of multifocal choroiditis will become better defined.

The disease affects otherwise healthy young patients in their third decade (average age, 34 y; range, 6-74 y), with an incidence of bilateral involvement of 80%. [12] A moderate racial and gender predisposition exists, with approximately 66% of patients being white and 80% of patients being female. [12] As well, myopia is present in more than 85% of these individuals.

The principle presenting symptom is usually blurry vision with or without photophobia. Mild ocular pain may occur, accompanied by complaints of metamorphopsia, floaters, scotomas, and photopsia.

Presenting visual acuity may vary from 20/20 to light perception, with an average of 20/100. Clinical examination reveals a mild-to-moderate aqueous inflammation with cell and flare in approximately 50-60% of patients. Small- to medium-sized keratic precipitates may be present, as well as posterior synechiae and iris atrophy with nodule formation. Vitreous cellular infiltrates are present in more than 90% of patients.

As demonstrated in the image below, fundus examination reveals multiple, small, discrete yellow/gray-white spots that are typically round and may be polygon or oval in shape.

These lesions are approximately 200 µm in diameter, but they can vary in size (50-1000 µm). The lesions tend to scatter predominantly in the periphery rather than in the macula and are located at the level of the RPE and choriocapillaris. Multiple active lesions may occur at any one time.

During the late stage of the disease, seen in the image below, the spots may become atrophic, with a rim of hyperpigmentation. These can assume the classic punched-out appearance with bands of subretinal fibrosis at their margins.

During the acute phase, optic disc edema may occur, which later develops to peripapillary scarring assuming a characteristic “napkin ring” subretinal fibrosis. [13] Periphlebitis is often present with resultant retinal vasculature narrowing. [14] Cystoid macular edema is present in approximately 10-20% of patients, and the incidence of choroidal neovascular membrane formation varies from 25-40%. [12, 15]

During the early stage, the active lesions exhibit blockage of the early fluorescence followed by late staining. A rim of hyperfluorescence may or may not be present around the lesions. With the late stage of the disease, the most predominant feature is that of RPE window defects corresponding to the areas of the lesions. (See the images below.)

Similar to findings on fluorescein angiography, early lesions of MCP are hypofluorescent on indocyanine green (ICG) angiography. In contrast, early lesions of POHS tend to be hyperfluorescent. [16, 17, 18]

The electroretinogram (ERG) is normal in approximately 50% of patients with MCP. However, a report by Jacobson and coworkers looking at ERG testing in patients with AZOOR, which included patients with MCP, revealed interocular asymmetry in all patients tested with full field ERGs. [2] In addition, moderate abnormalities in the a-wave suggest that there is dysfunction at the level of the photoreceptor outer segment. Similar findings have been noted in MEWDS and AMN using both the a-wave and the early receptor potential recordings. [19, 20] Serial multifocal ERG (MERG) testing reveals a diffuse loss of function over the entire test field that is often permanent. [21]

The electrooculographic (EOG) findings are abnormal in approximately 60% of patients studied. Visual field testing sometimes demonstrates increased blind spot size. [22] Scotomata are associated with clinical retinal lesions. Visual field pattern abnormalities correlate well with ERG a-wave amplitude. [2] In addition, large temporal field defects that do not correspond to clinical lesions have also been noted. [21]

The etiology of MCP remains unknown. Extensive systemic medical evaluations have not yet identified a single common cause for MCP. Unlike POHS, where 90% of patients exhibit positive reactions to the histoplasmin skin test, only 25% of patients with MCP exhibit positive reactions to this skin test. [23] Positive treponemal serology is evident in up to 27% of patients with MCP, yet no modification of the disease with penicillin treatments has been achieved to date.

Radiologic investigations of patients with MCP have demonstrated hilar adenopathy in a small minority of patients (approximately 4%) along with pulmonary calcification (approximately 10%). In conjunction with this, approximately 20% of patients with MCP have a positive Mantoux test. Half of those patients, when treated with antituberculous medications, have a decrease in the ocular inflammation. Sarcoidosis has also been diagnosed in more than one third of patients with MCP.

Other infections that have been associated with MCP include herpes simplex, herpes zoster, Epstein-Barr virus, Lyme disease, Toxocara canis, and West Nile virus. [24, 25, 26, 27, 28] Despite this, many investigators still believe that MCP results from an underlying autoimmune mechanism, possibly triggered by an infectious agent. Histopathologic studies of ocular specimens from patients with MCP have revealed a predominant B-lymphocyte and plasma cell infiltrate of the choroid and choriocapillaris. [29] In addition, a deposition of compliment and immunoglobulins at or above the Bruch membrane has been noted. A proliferation occurs of the pigment epithelium with hyperplastic changes and migration into the neurosensory retina. [29]

Unfortunately, recurrence is very high in MCP, and the visual prognosis remains poor. [30, 31, 32] Peripapillary atrophy with progressive subretinal fibrosis results in enlargement of a blind spot in approximately 43% of patients. [22, 33] Unlike the aforementioned conditions, the major cause of central visual loss is due to subretinal neovascular membrane formation (approximately 45%) and is not due to cystoid macular edema (approximately 13%). [34] Rarely, MCP may lead to serous retinal detachments. Approximately one third of patients with MCP maintain their initial visual acuity at onset, while another one third lose, on average, at least 2 or more Snellen lines. [30]

Treatment of MCP remains problematic. In a few cases, a prompt response occurs in the acute phase to high systemic corticosteroids with subsequent improvement in visual acuity. However, with each recurrence of the disease, a progressive diminution in the effect of corticosteroid treatment occurs.

Immunomodulatory therapy, using azathioprine, cyclosporine, or methotrexate, has often resulted in good control of the inflammation and in subsequent preservation of vision. [35] In some instances, amelioration of the subretinal neovascular membrane has been noted with corticosteroid therapy. [32] Specific laser therapies, both conventional laser therapy and photodynamic therapy (PDT), have been used with moderate success in managing subretinal neovascular membranes. [36, 37, 38] Surgical treatment of subretinal neovascular membranes involving limited macular translocation has also been reported. [39]

This very rare and incompletely characterized entity was first described in 1982. [40] Many investigators have long suspected that diffuse subretinal fibrosis syndrome (DSFS) represents a variation of MCP. As well, this condition shares many features of punctate inner choroidopathy and other similar diseases in the AZOOR group. [41] DSFS typically affects otherwise healthy individuals in their second decade (average age, approximately 20 y; range, 14-34 y). The condition is often bilateral. The association with axial myopia is questionable.

Patients typically present with central visual loss and complaints of metamorphopsia. Clinical examination during the acute phase reveals multiple, small, yellow stellate lesions scattered throughout the posterior pole. Mild vitritis may be present with isolated pockets of subretinal fluid. In the chronic phase, the lesions become discrete with sharply angulated subretinal scar formation, as in the image below. In the macula, the lesions tend to coalesce, forming broad zones of subretinal fibrosis. Later complications can include serous and hemorrhagic macular detachment. See the image below.

As mentioned earlier, this condition shares many clinical features with that of MCP. This is also reflected in the fluorescein angiogram. The distinct features of DSFS on angiography are an early phase hypofluorescence in the areas of subretinal fluid loculation. During the late phase of the angiogram, extensive leakage (seen in the images below) is present at these sites that, in some cases, may suggest subretinal neovascularization. [40]

The findings on the ERG and the EOG are notoriously variable in this condition, with surprisingly intact studies in individuals with both acute and chronic involvement. Visual field testing reveals constriction peripherally with central scotomata that often correlate with the clinical lesions.

As with MFC, no systemic associations with DSFS exist. Earlier suggestions that this condition may be due to as yet unknown hormonal irregularities in young women has not developed into any trend of significance. [42] In view of the clinical and angiographic findings, this condition’s clinical appearance is likely secondary to a primary RPE hyperplastic process. [43]

Histologic evidence of immunoglobulin and complement deposition on the internal side of the Bruch membrane also suggests a focal inflammation of the RPE. [29]

This condition is characterized by recurrent episodes with the fellow eye becoming involved within a 6-month period.

Management of DSFS involves the use of corticosteroids early in the disease. [41] This treatment is useful in sparing visual loss largely in the contralateral eye. Cyclosporin may be useful in those cases where steroid has failed to control the disease.

First described by Watzke and associates in 1984, punctate inner choroidopathy (PIC) typically affects young, moderately myopic women who present with typical signs of ocular histoplasmosis but have negative serology or skin test for histoplasmosis. [32, 44] This rare condition is also one of the entities grouped under AZOOR. [45] Other terms used to describe this condition include multifocal inner choroiditis and pseudohistoplasmosis. The average age of patients with PIC is 27 years with a range of 16-40 years. Females represent 90% of the patients with PIC and usually have bilateral ocular involvement. [46]

Patients present with blurred vision, photopsia, and central and peripheral scotomata; however, no history exists of any viral prodrome. PIC differs from POHS because patients with the latter tend to be more asymptomatic with regard to scotomata. Chronic chorioretinal scars also tend to be more stable in POHS than in PIC.

The initial visual acuity at presentation varies from 20/50 to 20/400. No anterior segment or external ocular signs of inflammation is evident. The characteristic lesion of PIC is essentially identical to that seen in ocular histoplasmosis with multiple (approximately 2-6) yellow-white spots (100-300 µm) of the inner choroid and retina largely confined to the posterior pole (see the image below). These lesions tend to assume a linear branching pattern. During the late stage of the disease, the spots become atrophic and pigmented.

The classic triad of punched-out peripheral lesions in association with peripapillary atrophic scar formation and disciform macular scar seen in POHS is often present in patients with PIC. Small serous retinal detachments may form; however, they resolve spontaneously and usually require no treatment. Both optic disc edema and the presence of vitreous cells appear to be a variable finding in patients with PIC. The occurrence of subretinal neovascular membranes in this condition is 25-40%.

Again, paralleling the findings in ocular histoplasmosis, the early phase of the angiogram demonstrates hyperfluorescence of the lesions, and the late phase (seen in the image below) is marked by leakage at the lesions.

The ERG findings are occasionally subnormal in patients with PIC. The electrooculogram demonstrates very mild abnormalities of the Arden ratio. Visual field testing demonstrates central and paracentral scotomas. An enlarged blind spot may or may not be present.

PIC likely represents a variant of MFC. This condition may represent either an inflammatory or infectious thrombosis of the choriocapillary layer by as of yet an unidentified organism that behaves very similarly to histoplasmosis.

Recurrences are common in PIC, usually occurring within the first 3 months. [32] Despite this, visual outcome is good with approximately 50-75% of eyes having vision better than 20/25, especially if uncomplicated with choroidal neovascular membrane formation.

A variable response to systemic corticosteroids occurs depending on the stage of the disease. [47, 48, 49] Both conventional laser therapy and PDT have been used for the management of subretinal neovascular membranes with increasing success. [50, 51, 52, 53]

In 1968, Gass first described acute posterior multifocal placoid pigment epitheliopathy (APMPPE). [54] This condition typically affects young or middle-aged, otherwise healthy, adults (average age, 25 y; range, 7-57 y) who experience an acute decrease in visual acuity in one or both eyes. [55, 56]

While neither a racial nor sex predilection is generally though to exist for this condition, a recent 20-year study of the incidence of white dot syndromes in Olmstead County Minnesota found that multiple evanescent white dot syndrome (MEWDS) occurred more commonly in females, and APMPPE occurred more often in males. [57] Bilateral involvement is generally the rule, although the second eye involvement may be delayed for several weeks.

The condition tends to resolve spontaneously in approximately 7-11 weeks with near-normal return of visual acuity and visual function in the majority of cases. Although some RPE changes may remain visible and small paracentral scotomas may persist, usually no other ocular disturbances are evident. The typical course of the disease suggests an underlying viral inflammatory disorder [1, 58] or a delayed type IV hypersensitivity reaction to multiple stimuli. [59]

A rapid reduction in visual acuity typically occurs with or without a history of a preceding flulike illness or upper respiratory tract infection. APMPPE presents clinically as multiple, well-circumscribed, flat lesions deep to the retina at the level of the RPE and choriocapillaris. The retina overlying the lesions appears normal. Subretinal fluid or neurosensory detachment over the lesions is very rare and should cause one to consider the diagnosis of Vogt-Koyanagi-Harada syndrome. These lesions are variable (approximately 0.125- to 1-disc diameter) in size, generally larger than those seen in retinal pigment epitheliitis, and are usually isolated but may be confluent. They are typically scattered throughout the posterior pole, including the macula, and in the postequatorial midperiphery. Initially, they appear cream-colored or grayish-white in color, as seen in the image below.

There is usually no evidence of anterior segment inflammation, although vitreous cells are present in as many as 50% of the patients. This may be the result of a mild periphlebitis with exudation. In addition to vascular inflammation, mild optic disc edema may also be noted. Very rarely, the condition can result in retinal edema, retinal hemorrhage, and choroidal neovascular membrane formation. [60]

Initially, the lesions demonstrate hyperautofluorescence with hypoautofluorescent margins. [61, 62, 63, 64] Hypoautofluorescence of the fovea on FAF may correlate with visual acuity impairment in the white dot syndromes, including APMPPE. [65]

The initial phase of the angiogram sometimes demonstrates prolonged filling of the choroidal vasculature. The acute phase lesions are hypofluorescent. This early hypofluorescence is often attributed to a combination of incomplete and irregular filling of the choriocapillaris in conjunction with a masking effect produced by the edematous, swollen RPE cells. This is followed in the late phase with evidence of leakage and staining at the lesion sites. See the images below.

The healed lesions of APMPPE demonstrate mottled hyperfluorescence and window-type defects due to alterations in the RPE in areas corresponding to the acute lesions.

The typical ICG pattern for both active and inactive lesions consists of hypofluorescent areas up to the late phase, suggesting choriocapillaris nonperfusion. [66, 67, 68, 69]

Initially, the active phase of the disease demonstrates an anterior displacement and hyperreflectivity of neuroretina and outer reflective bands in areas overlying affected RPE.

With resolution, there is an accompanying regression of the prior displacement, increased reflectance of the outer reflective band, and mild disruption of the outer retinal layers. Quiescent lesions display a nodular, hyperreflective lesion on the plane of the RPE, with mild underlying backscattering from the choroidal layer, consistent with RPE atrophy. [62, 64, 70, 71, 72]

A recent SD-OCT study of a case of acute APMPPE lesions, however, revealed a hyperreflective area located between the outer nuclear layer and the inner and outer photoreceptor segments (IS/OS junction) corresponding to the placoid lesions seen clinically and angiographically. [73] This finding suggests that the whitish placoid lesions seen clinically in APMPPE may represent edema between the outer nuclear layer and the IS/OS junction rather than swelling or opacification of the RPE cells.

Goldenberg and colleagues have proposed a 4-stage classification system for APMPPE based on Spectralis SD-OCT findings in a study of 12 eyes of 6 patients. [74]

In stage 1a, the hyperacute phase of the placoid lesions, there is a well-demarcated dome-shaped elevation of the IS/OS junction with hyperreflective intertwined material and variable amounts of subretinal fluid present beneath the IS/OS junction and the RPE. In Stage 1b, the acute phase lesion, there is a fairly rapid flattening of the well-demarcated dome-shaped lesion accompanied by thickening of the IS/OS junction and hyperreflectivity of the outer nuclear layer.

Within about 2 weeks, the lesion evolves into stage 2, a subacute phase, with a distinct separation of the IS/OS junction and RPE layer visible with mild subretinal fluid accumulation present. The hyperreflectivity of the outer nuclear layer begins to fade and the layer thins at this stage.

In Stage 3, the late phase, which occurs approximately 6 weeks post disease onset, there is partial disappearance of the IS/OS junction and accentuated hyperreflectivity of the RPE is seen.

At 3 months post onset, stage 4, or resolution phase, is visible. In it, 2 hyperreflective bands indicative of the IS/OS junction and the RPE reappear as separate and distinct bands.

Montero et al reported a case of APMPPE with severe intraretinal edema with large cysts present in the outer nuclear layer and disruption of the IS/OS junction on SD-OCT. [75] The intraretinal edema and structural abnormalities normalized with disease resolution. Others have demonstrated photoreceptor layer changes in both the acute and resolved stages of APMPPE on SD-OCT. [76]

Most patients with APMPPE have normal EOG findings. However, some patients may have diminished, subnormal EOG findings during the acute phase of the disease. Some may exhibit subnormal cone and rod ERG findings. Scotomata on visual-field testing often are present during the acute phase of the disease that may or may not be coincident with the observable clinical lesions. These scotomata can persist and be permanent.

The underlying etiology of APMPPE is unknown. Deutman and Van Buskirk believed that APMPPE represents a primary obstruction of the choroidal circulation with secondary RPE degeneration. [77, 78] This view is supported by ICG angiographic and OCT scan evidence. [66, 67, 68, 69, 64, 70] However, others, especially Gass, believe this to be a primary disease of the RPE. [1, 54] In view of this condition’s association with a viral flulike illness, it is possible that an immune reaction to shared viral and RPE antigens with or without modification by the use of antibiotics might be underlying any primary RPE involvement. Krey has been able to experimentally reproduce APMPPE-like lesions in the posterior poles of rabbits and rhesus monkeys infected with Borna disease virus (BDV). [79]

APMPPE, of all the conditions described in this article, has the greatest variety of associations with other systemic conditions and complications, as follows [63, 80, 81, 82, 83, 84, 85, 86, 87, 88] :

Thyroiditis [83, 89]

Platelet aggregation abnormalities

Lymphadenopathy

Renal cell carcinoma [82]

Systemic mycobacterial infections [90]

Hepatomegaly

Erythema nodosum [78, 91]

Regional enteritis

Cerebrovasculitis [85, 87, 91, 92, 93, 94]

Recurrent stroke [94]

Juvenile pontine infarction [95, 96]

Recurring meningoencephalitis [97]

Cranial nerve VI paralysis [98]

Vitamin B-12 deficiency [85]

Homocysteinemia [85]

Sarcoidosis [91, 99]

Lyme disease [63, 100]

Microvascular nephropathy [101]

DRESS syndrome [102]

Hemophagocytic syndrome [88]

Dysacusis [103]

Adenovirus type V [84]

Reaction to Swine Flu Vaccine [80]

Following influenza vaccination [104]

Spinal fluid pleocytosis and elevated cerebral spinal fluid (CSF) protein

The association between APMPPE and cerebral vasculitis is well known. Gass suggested that APMPPE may be the initial manifestation of primary CNS angiitis. [105] Mortality from the later condition is high, especially when associated with a rapid taper of systemic steroids. [73, 106, 107] A case of recurring meningoencephalitis has also been reported with APMPPE with prednisone tapering. [97] Because of the CNS associations with APMPPE, neurologic symptoms and signs in these patients should be investigated appropriately.

Over a 2- to 6-week period, the acute lesions begin to fade, leaving pigment mottling and atrophic, geographic-shaped lesions at the level of the RPE. Improvement in visual acuity often lags the resolution of the RPE lesions, which can take from weeks to months. Fortunately, the prognosis for visual recovery is very good, and many patients (75-80%) experience better than 20/40 vision. [108, 109] Some eyes remain symptomatic, however, and visual acuity remains reduced in up to 40% if there is foveal involvement at presentation. [109] Recurrences, unlike other conditions in this section, are rare, and usually occur within the first 6 months. [110] If there is initial unilateral presentation, the second eye often lags the first eye by a few days or weeks. A variant of APMPPE occurring in older patients and complicated by subsequent geographic atrophy and choroidal neovascular membrane formation has been described. [111]

Treatment of the acute phase of APMPPE with corticosteroids is common but has shown limited benefit. Treatment with the tumor necrosis factor (TNF) blocker infliximab has been reported to show improvement in visual acuity and prevention of recurrences during the follow-up period. [112] However, treatment with infliximab did not prevent disease spread to the contralateral eye. Sub-Tenon and intravitreal triamcinolone has been used for associated complications, such as macular edema and choroidal neovascularization. [113, 114] Sporadic treatments with antituberculous and systemic antibiotics have also been reported but have not, as of yet, been proven to be effective. [115]

Photodynamic laser therapy has also been used to manage choroidal neovascularization in this condition, as has the anti-VEGF agent ranibizumab. [113, 116] Immunosuppressive therapy with azathioprine [97] and with mitoxantrone [93] have been used successfully in the treatment of meningoencephalitis and the cerebral vasculitis associated with APMPPE, respectively.

This very rare condition was first described by Krill and Deutman in 1972. [117] Acute retinal pigment epitheliitis (ARPE) is a self-limited disease of the RPE that typically occurs in young, otherwise healthy adults. It has a median age of onset of approximately 45 years, with a range of 16-75 years. A preponderance of involvement is evident in males (approximately two thirds). No racial predilection exists, and the condition is bilateral in approximately 40% of patients.

Approximately half the patients are asymptomatic at the time of presentation, with the symptomatic patients describing a sudden, usually mild, decrease in vision with or without central or paracentral scotomata and metamorphopsia. Unlike APMPPE, many patients (approximately 75%) have visual acuities around 20/30. The lesions appear dark gray to black in color, with a surrounding yellow-white halo, and are typically between 50-100 µm in size. Often, 1-4 golden-colored spots are arranged in discrete clusters around the macula. With resolution, the spots may either darken or lighten, but the halos remain. Extramacular lesions are rare, and, with time, a pattern of RPE migration may develop at the sites of the spots. Very rarely, this condition is associated with macular edema or vitreitis. [118, 119] See the image below.

During the acute phase of the disease, the centers of the spots are hypofluorescent owing to blockage. The surrounding halos typically demonstrate light hyperfluorescence early, which is due to a window-type defect rather than dye leakage. [120, 121]

Early and midphase ICG angiography shows patchy hyperfluorescence in the macula, and late-phase frames show hyperfluorescent halos around the individual lesions, with a cockadelike appearance of the macula. [121] These angiographic abnormalities tend to resolve over time.

Limited time-domain OCT scanning studies of acute retinal pigment epitheliitis have demonstrated an abnormal foveal hyperreflectivity involving the outer nuclear layer and photoreceptors, with variable disruption of the retinal pigment epithelium and moderate backscattering. [122]

SD-OCT shows disruption of the IS/OS junction of the photoreceptors and a wider disruption of the inner band of the RPE layer. [121] SD-OCT in the acute phase may also show undulation of the RPE and backscattering, similar to TD-OCT. [123] The inner segment and outer segment layers and RPE inner band typically show restoration of normal anatomy with disease resolution, and restoration of the foveal IS/OS junction may be of prognostic value for visual recovery. [123] Whether the outer retinal involvement seen in these OCT studies is a primary or secondary response is unknown.

On Amsler grid testing, these patients sometimes describe variable central or paracentral scotomas. [119] Mild color vision abnormalities also have been described with this condition. ERG testing is generally normal, while EOG testing has yielded various results, from normal to subnormal depending on the extent of RPE involvement. With resolution of the disease, there is a high rate of conversion back to normal in all tests.

To date, systemic investigations of patients with this rare condition have failed to yield any conclusive etiology, although a viral etiology is generally suspected in this condition. Associations with rubella, Borrelia burgdorferi (Lyme disease), influenza, and hepatitis C infections have been made. [12, 124, 125, 126] In some instances, this condition is a harbinger of central serous retinal choroidopathy (CSR). [127] A case of ARPE has been reported following the administration of intravenous bisphosphonate. [128]

ARPE has a self-limited course, usually with complete resolution over a 6- to 12-week period. [129] Recurrences have been reported to occur but are rare. [130]

Given the generally benign and self-limited course of this condition, no specific treatment is recommended.

First described in 1984 by Jampol et al, [131, 19] MEWDS is a self-limited condition that afflicts young, otherwise-healthy patients, usually in their second decade (average age is 28 y; range is 14-57 y), although cases involving children and elderly patients have been described. [132, 131] Its incidence in one 20-year study of white dot syndromes was approximately 0.45 case per 100,000 population per year. [57]

MEWDS shares many clinical and electrophysiologic features with acute idiopathic blind spot enlargement syndrome (AIBES) and other entities in the acute zonal occult outer retinopathy (AZOOR) group. [4, 7] Despite that commonality, MEWDS is believed to be uniquely distinguishable, warranting its own separate identification. [10, 133]

The condition usually presents unilaterally, with few instances of later contralateral ocular involvement. [134] There is a preponderance of the condition in women (approximately 75% of patients) and in patients who are highly myopic. [135] No racial predilection exists.

In addition to presenting with blurred vision, photopsia, and multiple paracentral scotomata, patients may also report symptoms of a flulike illness (approximately 25-50%). Initial visual acuities on presentation vary from 20/25 to 20/300 (average 20/100). Vitreous cells are noted in approximately 50% of patients, despite the absence of any anterior segment or external ocular signs of inflammation.

The characteristic lesions in MEWDS consist of multiple, small (approximately 100-200 µm in diameter), gray-white patches, with each patch being made up of smaller white to light orange-colored dots. These lesions clinically appear to be at the level of the outer retina or RPE and typically are distributed in the perifoveal and peripapillary regions with rare involvement of the fovea itself. (See the image below.)

A circumpapillary presentation of MEWDS with corresponding blind spot enlargement can mimic the appearance of presumed ocular histoplasmosis syndrome. [136, 137, 138] In the periphery, the dots become sparse and assume a somewhat radial pattern, in some instances paralleling the retinal vasculature. Later, the macula often exhibits a fine, granular, white- or orange-speckled appearance, as demonstrated in the image below. [139, 140] These specks are much smaller than the white dots and often are associated with an irregular light reflex of the internal limiting membrane.

Other reported posterior pole findings include splinter hemorrhages, venous sheathing, panuveitis, hyperemia or edema of the optic nerve head, and, rarely, choroidal neovascularization. [141, 142, 143] Choroidal neovascularization can, in fact, be an initial presenting or early manifestation of MEWDS. [144, 145]

Fundus autofluorescence (FAF) has shown both hyperautofluorescence and hypoautofluorescence of the spots, corresponding to the hypofluorescent lesions seen on ICG angiography. [139, 146, 147, 148] The FAF lesions generally appear less numerous than the focal hypofluorescent spots seen on ICG angiography. [146, 148] With disease resolution, the spots usually evolve into areas of decreased autofluorescence or disappear altogether. [146, 147]

In the early phase of the fluorescein angiogram, there is a punctate hyperfluorescence of the gray-white patches that often displays a wreath-shaped pattern. Leakage of dye at the optic disc is present in approximately 60% of patients. During the late phase of the angiogram, represented in the image below, a patchy, mottled pattern of hyperfluorescence is observed throughout the posterior pole, with staining of the optic nerve head. With resolution of the acute episode, the angiographic findings become much less prominent; however, subtle RPE window defects usually persist. [149] See the image below.

ICG angiography studies have demonstrated multiple deep, small, round, hypofluorescent choroidal lesions appearing early and persisting into the late phases [150] of the disease. In some instances, the late phase hypofluorescence can appear as a series of small dots overlying larger spots. Many more lesions usually are observed on ICG angiography than are visible by clinical examination or fluorescein angiography. [151, 152, 153] The hypofluorescent lesions in the ICG angiogram persist for a longer time than do those lesions displayed during fluorescein angiography. [154, 155] The ICG-defined lesions also closely correlate with visual function. [16] ICG angiography in MEWDS can be helpful in establishing the diagnosis in cases with subtle fundus findings, and may also provide some useful guidance for therapy. [156, 149]

OCT scanning performed during the acute phase of MEWDS demonstrates moderately reflective focal lesions in the outer photoreceptor layer and a disruption of the foveal photoreceptor outer segments and the inner segment–outer segment (IS/OS) junction. [149, 157, 158, 159, 160] SD-OCT also demonstrates increased retinal pigment granularity in the affected eye in MEWDS. [161] One SD-OCT study showed decreased photoreceptor outer segment length in the acute phase of the disease with restoration to normal as the disease resolved. [162]

Reflectivity maps created from 3-dimensional SD-OCT data analysis have shown that disruptions of the IS/OS junction correspond to the hypofluorescent spots seen on ICG in the acute phase of MEWDS. [158] Line scans obtained through active white spot lesions show a dome-shaped, hyperreflective region in the subretinal space, with increased hyperreflectivity in the underlying choroidal space.

With resolution of the spots, the OCT scan abnormalities gradually reverse. [163] OCT scans obtained through the enlarged blind spot region show thinning of the outer nuclear layer in addition to IS/OS junction defects. [133, 149, 159] The information obtained from OCT scanning suggests that the principal defect in MEWDS occurs in the photoreceptor-RPE complex.

Despite clinical evidence of prominent RPE involvement in MEWDS, there is surprisingly only a brief manifestation of RPE dysfunction on electrophysiologic testing throughout most of the disease course. ERG performed during the acute phase demonstrates marked reduction in a-wave and early receptor potential (ERP) amplitudes, suggesting not only photoreceptor malfunction but also abnormal visual pigment regeneration kinetics. [19, 164] Selective cone ERG testing demonstrates predominantly more impairment of the S-cone system than of the L- and M-cone systems in the acute stage of MEWDS. [165]

Likewise, multifocal ERG testing has demonstrated not only reduction of amplitudes in areas corresponding to clinically visible lesions, but also in the remainder of normal-appearing retina. [21, 166, 167] It has also demonstrated abnormalities in asymptomatic and clinically normal-appearing fellow eyes. [149] Oscillatory potentials are reduced throughout the retina in patients with MEWDS, even in areas with normal multifocal ERG readings. [168] The reduced amplitudes on multifocal ERG testing persist for many months after normalization of both the fundus appearance and the psychophysical tests. [149, 169]

EOG testing demonstrates only mild abnormalities of the Arden ratio, again suggesting that the abnormalities in MEWDS occur mainly at the level of the photoreceptors and the cycling of visual pigments.

Visual field testing demonstrates not only paracentral and central scotomas but also enlarged blind spots. [133, 170, 171] Similarly, mapping regions of retinal sensitivity using microperimetry during the active phase of the condition demonstrates an enlarged blind spot. [172] Visual evoked potentials (VEP) have demonstrated prolongation of the P100 latency persisting for many months after resolution of symptoms, suggesting more significant optic nerve involvement than previously thought. [173]

The etiology of MEWDS remains unknown. The possibility of a viral cause has been considered in view of a history of a flu-like illness in a significant proportion of patients. MEWDS has been associated with hepatitis A and B vaccine, yellow fever vaccine, and human papilloma virus and meningococcus vaccines. further suggesting either a direct viral role or indirect viral antigen–induced response in the disease. [174, 175, 176, 177, 178]

The high prevalence of MEWDS in female patients also suggests that hormonal factors may play a role in this condition. Despite a report of increased serum immunoglobulins (IgM and IgG) in MEWDS, workups for systemic disease in MEWDS are usually negative. [179] An association between human leukocyte antigen B51 (HLA-B51) and MEWDS has been previously reported, possibly implicating a genetic predisposition for this disease. [180]

As has been suggested, MEWDS might also share a similar etiology with multifocal choroiditis. [133, 181] In addition, cases of primary intraocular lymphoma and sympathetic ophthalmia have been described as presenting with an MEWDS-type appearance. [182, 183, 184] This is important in differentiating true etiologic factors from other conditions that mimic MEWDS.

The disease usually has a self-limited course with good visual recovery, typically occurring within a 2-month period from the onset of symptoms (varies 2-16 wk). Approximately 90% of patients have better than 20/30 final visual acuity. Although late recurrences occasionally may occur, MEWDS is characterized by recovery of visual function and normalization of OCT and ERG findings. [163, 185] There is a return of normal peripheral funduscopic appearance, although macular changes (ie, foveal granularity) may persist. Long-term follow-up of patients is critical, because in rare cases, choroidal neovascularization can develop. [186, 144] Spaide et al report that AZOOR may develop in patients with MEWDS and that the subsequent development of AZOOR in these patients may be associated with a poorer visual prognosis. [133]

In general, due to its self-limited course, no treatment for MEWDS is generally needed or indicated. Systemic therapy with cyclosporine and corticosteroids have been described for isolated cases, with moderately good results. [187, 188] The use of photodynamic lasers and of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab has been effective in treating MEWDS cases complicated by macular edema or choroidal neovascularization. [189, 190]

Franceschetti and Babel may have incompletely described this chronic condition as early as 1949. [191] First named by Ryan and Maumenee in 1980 to describe a rare, acquired, bilateral intraocular inflammatory disease, the condition also has been called vitiliginous chorioretinitis partly because of its fundus appearance and its loose association with cutaneous vitiligo in earlier reports. [192] It typically involves middle- to late-aged patients (average age is approximately 52 y; range is 23-70 y). The disease primarily affects Caucasians, and, in the older age groups, especially beyond the fourth decade, females outnumber males.

Patients typically present with not only decreased visual acuity but also symptoms of nyctalopia and dyschromatopsia. Rarely, patients may complain of photophobia and a reduction in visual field. The condition is painless. On clinical examination, minimal to no anterior segment inflammation is present. Visual acuities may vary at onset from 20/20 to 20/800, with most patients having a visual acuity of approximately 20/50.

The characteristic appearance of lesions in birdshot consists of multifocal patches of RPE and choroidal depigmentation seen below.

Unlike other conditions in these syndromes, a halo of hyperpigmentation is absent within or at the lesion margins. Individual lesions are typically 0.25-disc diameter in size and have certain uniformity in appearance. They can be cream-colored or depigmented and round to oval in appearance and typically do not have a well-defined border. Hyperpigmentation may occur in some lesions in the late stages of the disease.

The lesions typically are scattered throughout the post-equatorial fundus in 1 of 4 patterns: (1) diffuse, (2) macular sparing, (3) macular predominance, and (4) asymmetrical. [193] Often, the pattern is analogous to the splattering of birdshot from a shotgun. Initial foveal sparing is present. Birdshot can be associated with other retinal and ocular abnormalities, as follows: [194, 195]

Cystoid macular edema

Retinovascular attenuation

Retinovascular sheathing

Retinal and vitreous hemorrhages

Epiretinal membrane formation

Glaucoma optic atrophy

Rhegmatogenous retinal detachment

Subretinal neovascularization

Optic disc edema (very rare)

Retinal neovascularization (very rare)

Serous macular degeneration (very rare)

The fundus lesions of birdshot retinochoroidopathy generally appear more numerous and are more readily visible with fundus autofluorescence imaging compared with color fundus photographs, especially in eyes with blonde fundi. [196] The FAF findings usually consist of a circumferential hypoautofluorescence around the optic nerve head; multifocal hypoautofluorescent areas in the posterior pole, which may or may not correspond to the hypopigmented birdshot lesions; and linear hypoautofluorescent streaks along the retinal vessels. [197] Some eyes also show placoid hypoautofluorescence in the macula, indicating RPE atrophy, and this may be an explanation for the decreased visual acuity in patients with birdshot retinochoroidopathy. [197]

The key fluorescein angiographic findings in birdshot result from vascular leakage. This is quite pronounced in the perifoveal region with resultant cystoid macular edema. Acutely, the patches in birdshot are surprisingly silent, showing no fluorescein abnormalities. With time and subsequent atrophy of the RPE, the individual lesions behave as window defects transmitting underlying fluorescence from the choroid.

In the early phase of the angiogram, there is a delay in retinal arteriole filling and circulation time, although retinal capillary nonperfusion typically is not seen with this disease. During this phase, the lesions are either not evident or are hypofluorescent. Choroidal vessels are often visible through the hypofluorescent lesions. With the late phase, the patches become hyperfluorescent, as demonstrated in the image below, with staining of the larger retinal veins and pooling of dye, particularly in the setting of cystoid macular edema. Prolonged retinal circulation time has been noted in birdshot. [198]

In general, ICG angiography reveals a greater number of lesions than is evident either funduscopically or on fluorescein angiography. [193] During the active phase of the disease, well-demarcated, hypofluorescent, round to oval spots appear throughout the posterior pole with relative sparing of the macula. [66] These spots appear early during the arteriovenous phase and persist unchanged during the late phase of the angiogram.

Progressive diffuse background fluorescence often occurs in the late phase of the angiogram in active disease. In the chronic or burned-out phase of the disease, ICG angiography reveals persistence of the characteristic hypofluorescent spots with absence of diffuse late phase hyperfluorescence. [199] Remarkably, the ICG lesions are preserved despite an improvement in clinical appearance of the fundus lesions.

ICG angiography may be particularly useful in the early diagnosis of birdshot retinochoroidopathy, when the typical birdshot lesions are either absent or poorly seen on clinical examination. [200]

The ERG in birdshot typically displays moderate-to-severe abnormalities of both rod and cone function (less than or equal to 80% of patients). A disproportionate decrease occurs in the amplitude of the b-wave compared with the a-wave (as demonstrated in the image below), and some believe that this decrease is the distinguishing feature of the disease. [201]

The 30-Hz flicker implicit time is abnormal in up to 70% of patients with birdshot retinochoroidopathy, and normalization of this ERG parameter may be a useful indicator that patients can be successfully tapered from immunomodulatory therapy. [202]

The EOG findings may be either normal or slightly subnormal (70% of patients), and dark adaptation studies may show subnormal rod function. Patients also may exhibit nonspecific color vision defects. The visual field demonstrates a generalized constriction of peripheral fields with central scotomas or enlarged blind spots. These scotomas do not correspond clinically to the birdshot lesion distribution. Serial automated visual-field testing has been found to be useful in the monitoring of the response to therapy. [203] Microperimetry of the macula has been suggested as another means to evaluate disease activity and assess visual impairment in birdshot retinochoroidopathy. [204]

Birdshot is believed to result from a pathologic process occurring not only in the receptor-RPE-choroid complex but also a pathologic process occurring more diffusely throughout the neural layers of the retina. A genetic predisposition has been suggested since the incidence of the human leukocyte antigen A29 (HLA-A29) marker is present in approximately 85-96% of patients with birdshot retinochoroidopathy. [205] This incidence rate is to be contrasted with 7% prevalence in the normal population. [206] The HLA-A29:02 subtype is the most predominant in Caucasian patients with the disease. [193, 205]

An autoimmune mechanism as the cause of birdshot is supported by several findings. First, in vitro studies demonstrating lymphocyte-mediated immune responses to retinal S-antigen are present in most patients tested. [207, 206] Second, histologic examination reveals a cell-mediated inflammatory response to the outer retina and focal depigmentation of the choroidal melanocytes. [193] Birdshot also has been associated with cutaneous vitiligo, elevated C4 complement, and elevated soluble interleukin (IL)–2 receptors, [208] as well as elevated intraocular levels of the proinflammatory and T cell–associated cytokines IL-1β, IL-17, tumor necrosis factor-α. [209]

Therefore, an altered immune mechanism likely is responsible for the clinical findings of this disease. As in the case of MEWDS, primary intraocular lymphoma may masquerade as birdshot retinochoroidopathy, and the lack of response to systemic immunosuppression therapy should lead to a reevaluation of the diagnosis. [210]

Birdshot retinochoroidopathy, unlike the aforementioned conditions, is a fairly chronic disease with slow progression. It can be active for 3-4 years before finally going into remission. [207] Although 73% of eyes have a visual acuity better than 20/60, ultimately, one third of patients have a final visual acuity of less than 20/200. The causes of central visual loss in patients with birdshot are the presence of cystoid macular edema (40-60% of patients) [193] and RPE atrophy in the macula. [197] Rarely, the condition can resemble advanced tapetoretinal degeneration, particularly when untreated. [211, 212]

Currently, no single therapy has proven effective for treating patients with this condition. Various nonsteroidal anti-inflammatory drugs, corticosteroids, and systemic immunosuppressive agents have been tried with limited efficacy. Corticosteroid therapy in both local and systemic forms often is tried initially for moderate disease. Good control sometimes can be achieved with an initial induction followed by a slow taper to a maintenance dose. [213] In situations where recurrence and exacerbation of the disease is present, a combination of azathioprine and prednisone may be effective in reducing the relapse rate. [214]

Rush et al reported the use of an intravitreal sustained-release fluocinolone acetonide–containing device in the treatment of 36 eyes of 22 patients with birdshot retinochoroidopathy. [215] That study showed the fluocinolone intravitreal implant can successfully control intraocular inflammation, decrease cystoid macular edema, and reduce or eliminate the need for systemic immunosuppressive therapy, but at the expense of high incidences of intraocular hypertension, glaucoma, and cataract.

Intravenous polyclonal immunoglobulin (IVIG) treatment has been reported in the past to be effective in achieving significant remission without the use of corticosteroids or cytotoxic agents. [216]

Recently, low dose (7.5-25 mg/wk) methotrexate has been reported to be effective in the treatment of birdshot retinochoroidopathy and was associated with a better long-term visual outcome compared with untreated patients and those treated with corticosteroids. [217]

Cyclosporine A has been demonstrated to have an ameliorating effect on birdshot, both as a single agent and in combination with prednisone. [193] A combination of systemic cyclosporine A and mycophenolate mofetil therapy resulted in control of inflammation for at least 1 year in 67% of birdshot retinochoroidopathy patients in one study. [218] Reports using a combination of ketoconazole and cyclosporine therapy have shown it to be effective not only in controlling the disease, but also achieving stability with much lower doses of cyclosporine than conventionally used. [219, 220]

Finally, the newer biologic agents, including infliximab, etanercept, and adalimumab may be considered for use in the treatment of cases of refractory uveitis, although experience with these agents is somewhat limited. [221, 222, 223, 224, 225] Recently, Kruh and coworkers reported obtaining clinical remission in 72 (81.8%) of 88 patients with refractory noninfectious uveitis, including 13 with birdshot chorioretinopathy, using infliximab. [226]

Serpiginous choroiditis, geographic choroiditis or choroidopathy, or geographic helicoid peripapillary choroidopathy is a rare, chronic, recurrent, and progressive choroiditis of unknown etiology that manifests a characteristic geographic or snakelike pattern of inner choroidal and RPE, and secondarily outer retinal atrophy. This condition was first described in 1932 by Junius, but it was not until 1974 that Shatz, Maumenee, and Patz characterized the condition more completely. [227, 228] Hamilton and Bird also described this condition in the same year. [229]

The disease typically affects otherwise healthy patients in their fourth to sixth decades. This condition is more prevalent in Caucasians, and no gender predilection exists. The condition may present unilaterally; however, with time, all cases eventually become bilateral. The interval between the primary and contralateral eye involvement may be several years.

Patients typically complain of blurred vision in association with metamorphopsia and central or paracentral scotomas. Clinical examination during the acute phase reveals an initial visual acuity of approximately 20/40 (range 20/20 to counting fingers, dependent on extent of foveal involvement). Although a nongranulomatous uveitis may occasionally be present, both anterior segment and external ocular examinations are usually unremarkable. [230] Vitritis may be present in up to 33% of patients. [231, 232]

The characteristic lesion of serpiginous choroiditis is a yellow-to-gray geographic lesion with a slightly fuzzy appearance, but usually with well-defined borders. The lesion typically arises from the peripapillary region and spreads centrifugally in a geographiclike or, as in the image below, pseudopodlike fashion. Although rare, cases have been reported in which the macula initially is affected. [233, 234] This variant is termed macular serpiginous choroiditis and, not surprisingly, carries a worse visual prognosis compared with typical serpiginous choroiditis. [235, 236, 237] Regions of quiescent atrophy are present in the wake of the advancing, active border of the lesion. Multiple areas of activity can be present in an eye at the same time, and isolated, noncontiguous areas of activity may be present, but both of these are fairly rare.

With time, pigment clumping, hypopigmentation of the RPE, and fibrous scar tissue formation occurs, with clear visibility of the underlying larger choroidal vessels within these atrophic patches. [238] Chronic recurrent or untreated disease may result in lesions present out to the equator of the eye, and large areas of the fundus may eventually be involved by the disease. Despite bilateral involvement, a high degree of asymmetry between both eyes is often present.

Unfortunately, this condition has a predilection for the temporal rather than the nasal fundus. Although the retina overlying the active lesion is usually edematous, and may develop a serous detachment, the retinal vessels and the optic nerve head usually appear normal throughout the disease. Choroidal neovascularization develops in approximately 25% of patients. [239, 240] Other reported posterior segment complications of serpiginous choroiditis include retinal periphlebitis, retinal and disc neovascularization, branch retinal vein occlusion, RPE detachment, cystoid macular edema, and bilateral macular holes. [234, 241, 242, 243, 244] Tang and colleagues reported a case of antiphospholipid antibody syndrome mimicking the clinical and angiographic appearance of serpiginous choroiditis. [245] Eales disease and acute retinal necrosis have also been reported in association with serpiginous choroiditis. [246, 247, 248]

The FAF images of serpiginous choroiditis vary depending on whether the lesion imaged is one of active inflammation, transitional, or old inactive inflammation. [249, 250] New acute lesions show a hypoautofluorescent spot or area along the border of a more hypoautofluorescent old lesion. [250] Within 2-5 days, a new lesion develops hyperautofluorescence and may exhibit a border of hypoautofluorescence, which corresponds to a thin rim of RPE depigmentation that can be seen clinically. [250] Over the next several weeks, the acute lesion evolves from a granular to a speckled hyperautofluorescent pattern. [250] As the lesion heals and becomes inactive, the affected RPE atrophies and degenerates, and the autofluorescence is lost. [250]

Old, inactive lesions are largely hypoautofluorescent. The detection of new areas of hyperautofluorescence along the borders of old, inactive, hypoautofluorescent lesions is reported to be a sensitive, noninvasive method of detecting disease recurrences. [250, 251] The severity of vision impairment in serpiginous choroiditis correlates with the degree of foveal hypoautofluorescence. [251]

The angiographic appearance of serpiginous choroiditis also varies according to the state of the disease. The lesions in the acute phase of the disease demonstrate blocked fluorescence during the early transit phase of the angiogram. Light hyperfluorescence and staining as a result of active inflammation occurs during the late phases. This staining typically progresses from the periphery towards the center, similar to that seen with APMPPE. [247] The hypofluorescence during the early phase is attributed to a combination of both RPE cell edema and choriocapillaris nonperfusion. Staining of the vein walls may be demonstrated when focal areas of retinal phlebitis are present. [247]

The inactive stage of the disease is characterized by a patchy diminution of the early choroidal flush due to the destruction of the choriocapillaris, and in some cases of the larger choroidal vessels too. There is unmasking of the underlying choroidal vessel hyperfluorescence in areas of healed lesions, which have become atrophic scars. The staining at the margins of inactive lesions results from leakage of adjacent preserved choriocapillaris. (See the images below.)

In the very late phases of the angiogram, diffuse hyperfluorescence of the lesions occurs due to staining of the sclera and any fibrous tissues.

ICGA of acute lesions generally shows a uniformly hypofluorescent geographic area corresponding to the acute lesion throughout all phases of the study. [252] In some cases, the active lesion develops a hyperfluorescent border around the edges of the active lesion in the late phase. [252, 253] ICGA tends to show a larger area of choroidal involvement than either clinical fundus examination or fluorescein angiography. [252] Once healed, the lesions show a heterogeneous pattern of hypofluorescence on ICGA. [252]

Giovannini and coworkers classified serpiginous choroiditis into 4 stages based on a combination of FA and ICGA findings: (1) a subclinical or choroidal stage in which the lesions are hypofluorescent with faint edges detectable only by ICGA; (2) an active or retinal stage with clinical, FA, and ICGA evidence of lesions; (3) a subhealing stage with slight late hyperfluorescence of lesions on ICGA but no evidence of them on FA; and (4) an inactive or healed stage with areas of hypofluorescence with clearly defined margins on ICGA and areas of hyperfluorescence and staining on FA. [253, 254]

The active serpiginous lesion typically demonstrates hyperreflectivity of the outer retina and a “waterfall effect” behind it due to the alterations in the RPE and choriocapillaris layers on time-domain OCT. [255, 256] Spectral-domain OCT typically shows hyperreflectivity of both the outer retina and choroid along with disruption of the IS/OS junction. [257, 258]

The degree of ERG and EOG abnormality is correlated closely with the extent of clinically involved retina. [234] Unless there is extensive retinal involvement, as in long-standing or untreated disease, the ERG and EOG studies are usually normal or only mildly subnormal. [259] Visual-field testing reveals absolute or relative scotomata corresponding to clinical retinal lesions. Central, cecocentral, and paracentral scotomata are the predominant feature on visual-field testing. Microperimetry has shown dense scotomas corresponding to all atrophic or inactive lesions and some active lesions, and relative scotomas in clinically normal–appearing areas of the posterior pole and peripapillary areas, indicating possible subclinical inflammation or choroidal perfusion abnormalities. [260] In spite of extensive involvement of the macula in serpiginous choroidits, stable fixation was found in over 60% of eyes by microperimetry. [260]

The etiology of serpiginous choroiditis remains elusive, although it is known that the lesions appear to be at the level of the RPE and choriocapillaris. Histopathologic studies reveal that the disease is primarily a nongranulomatous choroiditis with a moderate, diffuse lymphocytic infiltration of the choroid. [261] The suggestion that serpiginous may be caused by immunologic mechanisms is strengthened by its association with the human leukocyte antigen A2 (HLA-A2) and human leukocyte antigen B7 (HLA-B7) histocompatibility and by the occurrence of other inflammatory lesions in the involved eye. [241] Evidence of serologic reaction to retinal S-antigen in affected patients lends further support to alterations in immune responsiveness. [233] Other associations with serpiginous and serpiginouslike choroiditis include sarcoidosis, tuberculosis, extrapyramidal dystonia, and elevated factor VIII-von Willebrand factor. [234, 262, 263, 264]

The disease is characterized by an episodic, but generally indolent and progressive, course with recurrences often going undetected until there is macular involvement. Reactivation of quiescent borders of single lesions can occur, and new activity may arise from independent foci in the peripheral fundus. Active lesions typically resolve in 6-8 weeks, but reactivations may not occur for months or even years. Fibrous metaplasia of the RPE develops within the area of chorioretinal atrophy in approximately 50% of patients. This is particularly prominent nasally and in the peripapillary region.

Serpiginous lesions in the macula, cystoid macular edema, and choroidal neovascularization can adversely affect central visual acuity. The contralateral eye may be involved within months or several years following the initial process in the involved eye. Christmas and colleagues found that 25% of patients have a visual acuity of 20/200 or worse in one eye on long-term follow-up. [265] Most patients, however, are able to maintain good central and peripheral function in at least 1 eye.

The current management of serpiginous choroiditis usually involves combination treatment with high-dose corticosteroids (1 mg/kg/day of oral prednisone or 1 g of pulse intravenous methylprednisolone for 3-5 days, followed by a tapering dose of oral prednisone over 1-3 months) to control the acute inflammatory disease and an immunosuppressive agent or immunomodulator needed to prolong remission and preserve good vision. [266, 267, 268, 269]

The combination of azathioprine, cyclosporine, and prednisone has been reported to provide early remission in 5 patients treated with this combination of three drugs. [270]

Chlorambucil or cyclophosphamide has been reported to be successful in 9 patients with active serpiginous choroiditis. [271]

Intravitreal steroids have been used, as has the fluoroquinolone acetonide intravitreal implant as alternatives to long-term systemic steroid use with its attendant complications. [272, 273, 274, 275, 276]

Sahin has reported a case of serpiginous choroiditis successfully managed with the alkylating agent cyclophosphamide and prednisone for initial control, and cyclophosphamide alone for suppression of recurrences for 1 year. [277]

The immunomodulators adalimumab and infliximab have also been used in the treatment of serpiginous choroiditis, [278, 279] but they are not recommended as first-line treatments. [280]

Both bevacizumab and ranibizumab have been used to successfully manage the complication of choroidal neovascularization in serpiginous choroiditis. [281, 282, 283, 284, 285]

Diffuse unilateral subacute neuroretinitis (DUSN), which is caused by the chronic subretinal migration of 1 of at least 2 species of nematodes, characteristically involves children or young adults with a slight male preponderance among patients. Patients are otherwise healthy and are often asymptomatic at time of presentation.

Patients often present quite late in the disease with typically poor visual acuities, usually less than 20/200. Those few cases that have presented during the acute period have demonstrated a moderate degree of vitritis with optic disc swelling and a variable anterior chamber reaction, with or without hypopyon.

The characteristic posterior pole findings are those of focal, gray-white or yellow-white spots developing in the deep layers of the retina and also at the level of the RPE. These normally develop within several days to weeks from the onset of symptoms. The lesions tend to cluster in the macula or juxtamacular region and typically last several days before fading. Occasionally, a subretinal worm (500-2000 µm length, 25 µm in width), such as that present in the eye below, can be seen.

In the inactive phase, the posterior pole exhibits extensive mottling of the RPE, assuming a pseudo–retinitis pigmentosa appearance. There is also extensive retinovascular narrowing and sheathing with optic atrophy. Subretinal neovascularization may develop at this stage. A mild to moderate anterior chamber and vitreous cell reaction may be present even in the inactive stage. The patient often has an afferent pupillary defect. Barbazetto et al reported that the active phase of DUSN can mimic the fundus appearance of a white dot syndrome. [286]

In the very early stage of the disease, angiogram findings may be entirely normal. If lesions are present, hypofluorescence of the lesions occurs during the early phase of the angiogram, and the lesions typically stain during the late phase. In addition, leakage occurs from the capillaries overlying the optic nerve, in addition to more diffuse perivenous leakage occurring in the retina. In a more typical late stage of the disease, an increase occurs in the background choroidal fluorescence due to extensive RPE dropout and loss of pigmentation. Hyperfluorescence, indicative of RPE atrophy, occurs in the periphery and the peripapillary regions, exhibiting fine, mottled hyperfluorescence, particularly in the macular region. (See the image below.) If a worm is present, it can be seen as a hypofluorescent lesion.

Often, a moderate-to-severe reduction in the ERG occurs. With later stages of the disease, a disproportionate decrease occurs with the b-wave amplitude relative to the decrease in the a-wave amplitude. In rare instances, the ERG may be extinguished.

Leading the list of suspected causative agents in this disease are the nematodes Toxocara canis (dog roundworm), Ancylostoma caninum (dog hookworm), and Baylisascaris procyonis (raccoon intestinal nematode). [46, 287] Clinically, 2 types of worms apparently have been described with this condition. They are differentiated by length. Smaller worms (400-1000 µm) and longer worms (1500-2000 µm) may wander in the subretinal space for many years and cause progressive ocular damage. However, the nematode may be found during any stage of the disease.

The worm often is located in the deep, white retinal exudative lesions. Surgical removal of a subretinal nematode in a patient with DUSN identified the causative organism as a third stage T canis larva. [288] Serologic testing for Toxocara is typically negative in patients with DUSN.

The damage caused by the organisms appears to involve a local toxic tissue reaction to the outer retina caused by the worm’s byproducts, in addition to a more diffuse toxic reaction affecting both the inner and the outer retinal tissues that is believed to be due to the host’s immunologic defenses. Eosinophilia infrequently is detected, and patients do not manifest evidence of systemic disease.

Histopathologic examination of the few eyes that have been examined with DUSN reveals a largely nongranulomatous vitritis, retinitis, and retinal and optic nerve perivasculitis. Low-grade, patchy, nongranulomatous choroiditis also is present. Extensive degeneration of the peripheral retina occurs, particularly of the posterior region within the arcades. Mild-to-moderate degenerative changes in the RPE also have been described. Not surprisingly, optic atrophy is a common feature of these eyes.

Following the acute phase of the disease, focal and more diffuse depigmentation of the RPE develops over the ensuing weeks or months. Pigment migration occurs into the overlying retina with a gradual narrowing of the retinal vasculature. Retinal hemorrhages may result from choroidal neovascularization and can result in occasional serous retinal detachments.

Treatment of patients with DUSN has not yet been optimized to date. Three modalities of treatment, of which a combination usually is applied, are available. Argon laser photocoagulation is effective in destroying the worm, but can cause an inflammatory reaction. Surgical (transvitreal) removal of a subretinal nematode elicits less inflammatory response but is accompanied with higher risks inherent to this treatment. The use of such medicinals as antihelminthics (eg, thiabendazole, diethylcarbamazine) or antifilarial agents (eg, Ivermectin) may be used as adjunctive treatment.

With the exception of DUSN, the idiopathic multifocal choroidopathy syndromes discussed remain problematic, not only from an etiologic point of view but also from a classification point of view. Although there is a practical benefit to combine these entities under one group, such as AZOOR or multifocal choroidopathy, sufficiently unique characteristics in each of these conditions still exist that make them distinct from each other. Additionally, many instances occur where the patient’s symptomatology and clinical findings overlap between the entities. Similarly, although many findings point toward an infectious and/or immunologic mechanism as the cause of these conditions, no conclusive evidence for either one has yet been demonstrated. Until more clinical and histologic information regarding these entities is available, current attempts at grouping or subgrouping these conditions proves inadequate in the long run.

Gass JD. Acute zonal occult outer retinopathy. Donders Lecture: The Netherlands Ophthalmological Society, Maastricht, Holland, June 19, 1992. J Clin Neuroophthalmol. 1993 Jun. 13(2):79-97. [Medline].

Jacobson SG, Morales DS, Sun XK, et al. Pattern of retinal dysfunction in acute zonal occult outer retinopathy. Ophthalmology. 1995 Aug. 102(8):1187-98. [Medline].

Francis PJ, Marinescu A, Fitzke FW, et al. Acute zonal occult outer retinopathy: towards a set of diagnostic criteria. Br J Ophthalmol. 2005 Jan. 89(1):70-3. [Medline].

Volpe NJ, Rizzo JF, Lessell S. Acute idiopathic blind spot enlargement syndrome: a review of 27 new cases. Arch Ophthalmol. 2001 Jan. 119(1):59-63. [Medline].

Machida S, Haga-Sano M, Ishibe T, et al. Decrease of blue cone sensitivity in acute idiopathic blind spot enlargement syndrome. Am J Ophthalmol. 2004 Aug. 138(2):296-9. [Medline].

Watzke RC, Shults WT. Clinical features and natural history of the acute idiopathic enlarged blind spot syndrome. Ophthalmology. 2002 Jul. 109(7):1326-35. [Medline].

Gass JD. Overlap among acute idiopathic blind spot enlargement syndrome and other conditions. Arch Ophthalmol. 2001 Nov. 119(11):1729-31. [Medline].

Kondo N, Kondo M, Miyake Y. Acute idiopathic blind spot enlargement syndrome: prolonged retinal dysfunction revealed by multifocal electroretinogram technique. Am J Ophthalmol. 2001 Jul. 132(1):126-8. [Medline].

Turbeville SD, Cowan LD, Gass JD. Acute macular neuroretinopathy: a review of the literature. Surv Ophthalmol. 2003 Jan-Feb. 48(1):1-11. [Medline].

Jampol LM, Wiredu A. MEWDS, MFC, PIC, AMN, AIBSE, and AZOOR: one disease or many?. Retina. 1995. 15(5):373-8. [Medline].

Nozik RA, Dorsch W. A new chorioretinopathy associated with anterior uveitis. Am J Ophthalmol. 1973 Nov. 76(5):758-62. [Medline].

Quillen DA, Davis JB, Gottlieb JL, et al. The white dot syndromes. Am J Ophthalmol. 2004 Mar. 137(3):538-50. [Medline].

Buerk BM, Rabb MF, Jampol LM. Peripapillary subretinal fibrosis: a characteristic finding of multifocal choroiditis and panuveitis. Retina. 2005 Feb-Mar. 25(2):228-9. [Medline].

Schenck F, Boke W. Retinal vasculitis with multifocal retinochoroiditis. Int Ophthalmol. 1990 Oct. 14(5-6):401-4. [Medline].

Krill AE, Archer D. Choroidal neovascularization in multifocal (presumed histoplasmin) choroiditis. Arch Ophthalmol. 1970 Nov. 84(5):595-604. [Medline].

Cimino L, Auer C, Herbort CP. Sensitivity of indocyanine green angiography for the follow-up of active inflammatory choriocapillaropathies. Ocul Immunol Inflamm. 2000 Dec. 8(4):275-83. [Medline].

Parnell JR, Jampol LM, Yannuzzi LA, et al. Differentiation between presumed ocular histoplasmosis syndrome and multifocal choroiditis with panuveitis based on morphology of photographed fundus lesions and fluorescein angiography. Arch Ophthalmol. 2001 Feb. 119(2):208-12. [Medline].

Vadala M, Lodato G, Cillino S. Multifocal choroiditis: indocyanine green angiographic features. Ophthalmologica. 2001 Jan-Feb. 215(1):16-21. [Medline].

Sieving PA, Fishman GA, Jampol LM, Pugh D. Multiple evanescent white dot syndrome. II. Electrophysiology of the photoreceptors during retinal pigment epithelial disease. Arch Ophthalmol. 1984 May. 102(5):675-9. [Medline].

Sieving PA, Fishman GA, Salzano T, Rabb MF. Acute macular neuroretinopathy: early receptor potential change suggests photoreceptor pathology. Br J Ophthalmol. 1984 Apr. 68(4):229-34. [Medline].

Oh KT, Folk JC, Maturi RK, et al. Multifocal electroretinography in multifocal choroiditis and the multiple evanescent white dot syndrome. Retina. 2001. 21(6):581-9. [Medline].

Khorram KD, Jampol LM, Rosenberg MA. Blind spot enlargement as a manifestation of multifocal choroiditis. Arch Ophthalmol. 1991 Oct. 109(10):1403-7. [Medline].

Dreyer RF, Gass DJ. Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Arch Ophthalmol. 1984 Dec. 102(12):1776-84. [Medline].

Bloom SM, Snady-McCoy L. Multifocal choroiditis uveitis occurring after herpes zoster ophthalmicus. Am J Ophthalmol. 1989 Dec 15. 108(6):733-5. [Medline].

Bodine SR, Marino J, Camisa TJ, Salvate AJ. Multifocal choroiditis with evidence of Lyme disease. Ann Ophthalmol. 1992 May. 24(5):169-73. [Medline].

Frau E, Dussaix E, Offret H, Bloch-Michel E. The possible role of herpes viruses in multifocal choroiditis and panuveitis. Int Ophthalmol. 1990 Oct. 14(5-6):365-9. [Medline].

Spaide RF, Sugin S, Yannuzzi LA, DeRosa JT. Epstein-Barr virus antibodies in multifocal choroiditis and panuveitis. Am J Ophthalmol. 1991 Oct 15. 112(4):410-3. [Medline].

Tiedeman JS. Epstein-Barr viral antibodies in multifocal choroiditis and panuveitis. Am J Ophthalmol. 1987 May 15. 103(5):659-63. [Medline].

Palestine AG, Nussenblatt RB, Chan CC, et al. Histopathology of the subretinal fibrosis and uveitis syndrome. Ophthalmology. 1985 Jun. 92(6):838-44. [Medline].

Vianna RN, Ozdal PC, Filho JP, et al. Longterm follow-up of patients with multifocal choroiditis and panuveitis. Acta Ophthalmol Scand. 2004 Dec. 82(6):748-53. [Medline].

Joondeph BC, Tessler HH. Clinical course of multifocal choroiditis: photographic and angiographic evidence of disease recurrence. Ann Ophthalmol. 1991 Nov. 23(11):424-9. [Medline].

Morgan CM, Schatz H. Recurrent multifocal choroiditis. Ophthalmology. 1986 Sep. 93(9):1138-47. [Medline].

Reddy CV, Brown J, Folk JC, et al. Enlarged blind spots in chorioretinal inflammatory disorders. Ophthalmology. 1996 Apr. 103(4):606-17. [Medline].

Watzke RC, Claussen RW. The long-term course of multifocal choroiditis (presumed ocular histoplasmosis). Am J Ophthalmol. 1981 Jun. 91(6):750-60. [Medline].

Michel SS, Ekong A, Baltatzis S, Foster CS. Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology. 2002 Feb. 109(2):378-83. [Medline].

Coquelet P, Postelmans L, Snyers B, Verougstraete C. Successful photodynamic therapy combined with laser photocoagulation in three eyes with classic subfoveal choroidal neovascularisation affecting two patients with multifocal choroiditis: case reports. Bull Soc Belge Ophtalmol. 2002. 69-73. [Medline].

Gebka A, Raczynska K, Ciechanowski C, Krajka-Lauer J. [Photodynamic therapy with verteporfin in treating the choroidal neovascularisation secondary to multifocal choroiditis]. Klin Oczna. 2005. 107(1-3):118-20. [Medline].

Gerth C, Spital G, Lommatzsch A, et al. Photodynamic therapy for choroidal neovascularization in patients with multifocal choroiditis and panuveitis. Eur J Ophthalmol. 2006 Jan-Feb. 16(1):111-8. [Medline].

Fujii GY, Humayun MS, Pieramici DJ, et al. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol. 2001 Jan. 131(1):90-100. [Medline].

Doran RM, Hamilton AM. Disciform macular degeneration in young adults. Trans Ophthalmol Soc U K. 1982. 102 (Pt 4):471-80. [Medline].

Gandorfer A, Ulbig MW, Kampik A. Diffuse subretinal fibrosis syndrome. Retina. 2000. 20(5):561-3. [Medline].

Salvador F, Garcia-Arumi J, Mateo C, et al. Multifocal choroiditis with progressive subretinal fibrosis. Report of two cases. Ophthalmologica. 1994. 208(3):163-7. [Medline].

Cantrill HL, Folk JC. Multifocal choroiditis associated with progressive subretinal fibrosis. Am J Ophthalmol. 1986 Feb 15. 101(2):170-80. [Medline].

Watzke RC, Packer AJ, Folk JC, et al. Punctate inner choroidopathy. Am J Ophthalmol. 1984 Nov. 98(5):572-84. [Medline].

Taira K, Nakazawa M, Takano Y, Ota T. Acute zonal occult outer retinopathy in the fellow eye 5 years after presentation of punctate inner choroidopathy. Graefes Arch Clin Exp Ophthalmol. 2005 Nov 29. 1-3. [Medline].

Gass JD. Stereoscopic Atlas of Macular Diseases Diagnosis and Treatment. St Louis: Mosby-Year Book Inc. 1987.

Brueggeman RM, Noffke AS, Jampol LM. Resolution of punctate inner choroidopathy lesions with oral prednisone therapy. Arch Ophthalmol. 2002 Jul. 120(7):996. [Medline].

Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol. 2005 Mar. 139(3):421-8. [Medline].

Levy J, Shneck M, Klemperer I, Lifshitz T. Punctate inner choroidopathy: resolution after oral steroid treatment and review of the literature. Can J Ophthalmol. 2005 Oct. 40(5):605-8. [Medline].

Chatterjee S, Gibson JM. Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy. Br J Ophthalmol. 2003 Jul. 87(7):925-7. [Medline].

Leslie T, Lois N, Christopoulou D. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol. 2005 Feb. 89(2):147-50. [Medline].

Lim JI, Flaxel CJ, LaBree L. Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease. Ann Acad Med Singapore. 2006 Mar. 35(3):198-202. [Medline].

Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol. 2003 Nov. 241(11):899-906. [Medline].

Gass JD. Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1968 Aug. 80(2):177-85. [Medline].

Burés-Jelstrup A, Adán A, Casaroli-Marano R. [Acute posterior multifocal placoid pigment epitheliopathy. Study of 16 cases]. Arch Soc Esp Oftalmol. 2007 May. 82(5):291-7. [Medline].

Mensah E, Vafidis GC. Acute posterior multifocal placoid pigment epitheliopathy in a 7-year-old girl. J Pediatr Ophthalmol Strabismus. 2002 Jul-Aug. 39(4):239-41. [Medline].

Abu-Yaghi NE, Hartono SP, Hodge DO, Pulido JS, Bakri SJ. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm. 2011 Dec. 19(6):426-30. [Medline]. [Full Text].

Holt WS, Regan CD, Trempe C. Acute posterior multifocal placoid pigment epitheliopathy. Am J Ophthalmol. 1976 Apr. 81(4):403-12. [Medline].

Park D, Schatz H, McDonald HR, Johnson RN. Acute multifocal posterior placoid pigment epitheliopathy: a theory of pathogenesis. Retina. 1995. 15(4):351-2. [Medline].

Garg S, Jampol LM. Macular serous detachment in acute posterior multifocal placoid pigment epitheliopathy. Retina. 2004 Aug. 24(4):650-1. [Medline].

Spaide RF. Autofluorescence imaging of acute posterior multifocal placoid pigment epitheliopathy. Retina. 2006 Apr. 26(4):479-82. [Medline].

Souka AA, Hillenkamp J, Gora F, Gabel VP, Framme C. Correlation between optical coherence tomography and autofluorescence in acute posterior multifocal placoid pigment epitheliopathy. Graefes Arch Clin Exp Ophthalmol. 2006 Oct. 244(10):1219-23. [Medline].

Framme C, Sachs HG, Gabler B, Roider J. Fundus autofluorescence in APMPPE in association with lyme disease. Retina. 2002 Oct. 22(5):653-7. [Medline].

Batioglu F, Ozmert E, Kurt R. Fundus autofluorescence and spectral optical coherence tomography findings in a case with acute posterior multifocal placoid pigment epitheliopathy. Ann Ophthalmol (Skokie). 2008 Fall-Winter. 40(3-4):185-9. [Medline].

Yeh S, Forooghian F, Wong WT, et al. Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol. 2010 Jan. 128(1):46-56. [Medline]. [Full Text].

Howe LJ, Stanford MR, Graham EM, Marshall J. Choroidal abnormalities in birdshot chorioretinopathy: an indocyanine green angiography study. Eye. 1997. 11 (Pt 4):554-9. [Medline].

Park D, Schatz H, McDonald HR, Johnson RN. Indocyanine green angiography of acute multifocal posterior placoid pigment epitheliopathy. Ophthalmology. 1995 Dec. 102(12):1877-83. [Medline].

Bouchenaki N, Cimino L, Auer C, Tao Tran V, Herbort CP. Assessment and classification of choroidal vasculitis in posterior uveitis using indocyanine green angiography. Klin Monatsbl Augenheilkd. 2002 Apr. 219(4):243-9. [Medline].

Schneider U, Inhoffen W, Gelisken F. Indocyanine green angiography in a case of unilateral recurrent posterior acute multifocal placoid pigment epitheliopathy. Acta Ophthalmol Scand. 2003 Feb. 81(1):72-5. [Medline].

Lim LL, Watzke RC, Lauer AK, Smith JR. Ocular coherence tomography in acute posterior multifocal placoid pigment epitheliopathy. Clin Experiment Ophthalmol. 2006 Nov. 34(8):810-2. [Medline].

Scheufele TA, Witkin AJ, Schocket LS, Rogers AH, Schuman JS, Ko TH. Photoreceptor atrophy in acute posterior multifocal placoid pigment epitheliopathy demonstrated by optical coherence tomography. Retina. 2005 Dec. 25(8):1109-12. [Medline].

Lofoco G, Ciucci F, Bardocci A, Quercioli P, Steigerwalt RD Jr, De Gaetano C. Optical coherence tomography findings in a case of acute multifocal posterior placoid pigment epitheliopathy (AMPPPE). Eur J Ophthalmol. 2005 Jan-Feb. 15(1):143-7. [Medline].

El Sanhouri A, Sisk RA, Petersen MR. Mortality from cerebral vasculitis associated with rapid steroid taper during treatment of acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 2012 Jul 1. 130(7):935-7. [Medline].

Goldenberg D, Habot-Wilner Z, Loewenstein A, Goldstein M. Spectral domain optical coherence tomography classification of acute posterior multifocal placoid pigment epitheliopathy. Retina. 2012 Jul. 32(7):1403-10. [Medline].

Montero JA, Ruiz-Moreno JM, Fernandez-Munoz M. Spectral domain optical coherence tomography findings in acute posterior multifocal placoid pigment epitheliopathy. Ocul Immunol Inflamm. 2011 Feb. 19(1):48-50. [Medline].

Cheung CM, Yeo IY, Koh A. Photoreceptor changes in acute and resolved acute posterior multifocal placoid pigment epitheliopathy documented by spectral-domain optical coherence tomography. Arch Ophthalmol. 2010 May. 128(5):644-6. [Medline].

Deutman AF, Oosterhuis JA, Boen-Tan TN, Aan de Kerk AL. Acute posterior multifocal placoid pigment epitheliopathy. Pigment epitheliopathy of choriocapillaritis?. Br J Ophthalmol. 1972 Dec. 56(12):863-74. [Medline].

Van Buskirk EM, Lessell S, Friedman E. Pigmentary epitheliopathy and erythema nodosum. Arch Ophthalmol. 1971 Mar. 85(3):369-72. [Medline].

Krey H. Ocular involvement in BDV-infected rabbits and primates. APMIS Suppl. 2008. 58-60. [Medline].

Fine HF, Kim E, Flynn TE, Gomes NL, Chang S. Acute posterior multifocal placoid pigment epitheliopathy following varicella vaccine. Br J Ophthalmol. 2008 Aug 26. [Medline].

Matsuo T, Horikoshi T, Nagai C. Acute posterior multifocal placoid pigment epitheliopathy and scleritis in a patient with pANCA-positive systemic vasculitis. Am J Ophthalmol. 2002 Apr. 133(4):566-8. [Medline].

Parmeggiani F, Costagliola C, D’Angelo S, Incorvaia C, Perri P, Sebastiani A. Clear cell renal cell carcinoma associated with bilateral atypical acute posterior multifocal placoid pigment epitheliopathy. Oncology. 2004. 66(6):502-9. [Medline].

Ruiz Viñals AT, Buil Calvo JA, Martínez Giralto O, Castilla Céspedes M. [Acute posterior multifocal placoid pigment epitheliopathy associated with Graves-Basedow’s disease]. Arch Soc Esp Oftalmol. 2002 Jul. 77(7):381-4. [Medline].

Thomson SP, Roxburgh ST. Acute posterior multifocal placoid pigment epitheliopathy associated with adenovirus infection. Eye. 2003 May. 17(4):542-4. [Medline].

Al Kawi A, Wang DZ, Kishore K, Kattah JC. A case of ischemic cerebral infarction associated with acute posterior multifocal placoid pigment epitheliopathy, CNS vasculitis, vitamin B(12) deficiency and homocysteinemia. Cerebrovasc Dis. 2004. 18(4):338-9. [Medline].

Bugnone AN, Hartker F, Shapiro M, Pineless HS, Velez G. Acute and chronic brain infarcts on MR imaging in a 20-year-old woman with acute posterior multifocal placoid pigment epitheliopathy. AJNR Am J Neuroradiol. 2006 Jan. 27(1):67-9. [Medline].

de Vries JJ, den Dunnen WF, Timmerman EA, Kruithof IG, De Keyser J. Acute posterior multifocal placoid pigment epitheliopathy with cerebral vasculitis: a multisystem granulomatous disease. Arch Ophthalmol. 2006 Jun. 124(6):910-3. [Medline].

Suzuki S, Mizota A, Adachi-Usami E. A case of hemophagocytic syndrome with retinal changes resembling acute posterior multifocal placoid pigment epitheliopathy. Retina. 2002 Apr. 22(2):219-22. [Medline].

Jacklin HN. Acute posterior multifocal placoid pigment epitheliopathy and thyroiditis. Arch Ophthalmol. 1977 Jun. 95(6):995-7. [Medline].

De Luigi G, Mantovani A, Papadia M, Herbort CP. Tuberculosis-related choriocapillaritis (multifocal-serpiginous choroiditis): follow-up and precise monitoring of therapy by indocyanine green angiography. Int Ophthalmol. 2012 Feb. 32(1):55-60. [Medline].

Prokosch V, Becker H, Thanos S, Stupp T. Acute posterior multifocal placoid pigment epitheliopathy with concurrent cerebral vasculitis and sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2010 Jan. 248(1):151-2. [Medline].

Pagnoux C, Thorne C, Mandelcorn ED, Carette S. CNS involvement in acute posterior multifocal placoid pigment epitheliopathy. Can J Neurol Sci. 2011 May. 38(3):526-8. [Medline].

Masse H, Guyomard JL, Baudet D, Pinel JF, Edan G, Charlin JF. Mitoxantrone therapy for acute posterior multifocal placoid pigment epitheliopathy with cerebral vasculitis. Case Report Med. 2009. 2009:481512. [Medline]. [Full Text].

Luneau K, Newman NJ, Srivastava S, Biousse V. A case of acute posterior multifocal placoid pigment epitheliopathy with recurrent stroke. J Neuroophthalmol. 2009 Jun. 29(2):111-8. [Medline].

Poppenborg M, Schabitz W, Rauch M, Spital G. [Juvenile pontine infarction. Complication of acute posterior multifocal placoid pigment epitheliopathy]. Nervenarzt. 2011 Apr. 82(4):496, 498-9. [Medline].

Jaramillo A, Gaete G, Romero P, Orellana P, Illanes S. Acute pontine infarct in a 16-year-old man with acute posterior multifocal placoid pigment epitheliopathy. A case report. J Stroke Cerebrovasc Dis. 2009 Mar-Apr. 18(2):164-6. [Medline].

Joswig H, Flueckiger C, Infanger A, Tettenborn B, Felbecker A. Recurring meningoencephalitis in sinusitis-associated acute posterior multifocal placoid pigment epitheliopathy under prednisone tapering. BMJ Case Rep. 2011 May 10. 2011:[Medline].

Gibelalde A, Bidaguren A, Ostolaza JI, Cortazar L, Irigoyen C. [Pigmentary epitheliopathy multifocal acute placoid associated with paralysis of VI cranial par]. Arch Soc Esp Oftalmol. 2009 Mar. 84(3):159-62. [Medline].

Darugar A, Mathian A, Lehoang P, Bodaghi B. Acute posterior multifocal placoid pigment epitheliopathy as the initial manifestation of sarcoidosis. J Ophthalmic Vis Res. 2011 Oct. 6(4):338-43. [Medline]. [Full Text].

Augsten R, Pfister W, Konigsdorffer E. [Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) and borreliosis]. Klin Monbl Augenheilkd. 2009 Jun. 226(6):512-3. [Medline].

Orlacchio A, Babalini C, Borreca A, et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain. 2010 Feb. 133:591-8. [Medline]. [Full Text].

Laban E, Hainaut-Wierzbicka E, Pourreau F, et al. Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and Epstein-Barr virus reactivation. Am J Kidney Dis. 2010 Mar. 55(3):e11-4. [Medline].

Clearkin LG, Hung SO. Acute posterior multifocal placoid pigment epitheliopathy associated with transient hearing loss. Trans Ophthalmol Soc U K. 1983. 103 ( Pt 5):562-4. [Medline].

Mendrinos E, Baglivo E. Acute posterior multifocal placoid pigment epitheliopathy following influenza vaccination. Eye (Lond). 2010 Jan. 24(1):180-1. [Medline].

Gass JDM. Stereoscopic Atlas of Macular Diseases diagnosis and treatment. Fourth edition. Mosby, St. Louis; 1997. Volume two: 668.

Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore). 1988 Jan. 67(1):20-39. [Medline].

Wilson CA, Choromokos EA, Sheppard R. Acute posterior multifocal placoid pigment epitheliopathy and cerebral vasculitis. Arch Ophthalmol. 1988 Jun. 106(6):796-800. [Medline].

Wolf MD, Alward WL, Folk JC. Long-term visual function in acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1991 Jun. 109(6):800-3. [Medline].

Fiore T, Iaccheri B, Androudi S, et al. Acute posterior multifocal placoid pigment epitheliopathy: outcome and visual prognosis. Retina. 2009 Jul-Aug. 29(7):994-1001. [Medline].

Saraux H, Pelosse B. Acute posterior multifocal placoid pigment epitheliopathy. A long-term follow-up. Ophthalmologica. 1987. 194(4):161-3. [Medline].

Taich A, Johnson MW. A syndrome resembling acute posterior multifocal placoid pigment epitheliopathy in older adults. Retina. 2009 Feb. 29(2):149-56. [Medline].

El-Markaby HS, Mohammed TH, El-Raggal TM. Acute Posterior Multifocal Placoid Pigment Epitheliopathy: Role of TNF Blocker in Severe Cases. Retina. 2012 Jun 15. [Medline].

Bowie EM, Sletten KR, Kayser DL, Folk JC. Acute posterior multifocal placoid pigment epitheliopathy and choroidal neovascularization. Retina. 2005 Apr-May. 25(3):362-4. [Medline].

Yenerel NM, Gorgun E, Dinc UA, Oncel M. Treatment of cystoid macular edema due to acute posterior multifocal placoid pigment epitheliopathy. Ocul Immunol Inflamm. 2008 Jan-Feb. 16(1):67-71. [Medline].

Teyssot N, Bodaghi B, Cassoux N, Fardeau C, Le Mer Y, Ullern M, et al. [Acute posterior multifocal placoid pigment epitheliopathy, serpiginous and multifocal choroiditis: etiological and therapeutic management]. J Fr Ophtalmol. 2006 May. 29(5):510-8. [Medline].

Mavrakanas N, Mendrinos E, Tabatabay C, Pournaras CJ. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy. Acta Ophthalmol. 2010 Mar. 88(2):e54-5. [Medline].

Krill AE, Deutman AF. Acute retinal pigment epitheliitus. Am J Ophthalmol. 1972 Aug. 74(2):193-205. [Medline].

Jamison RR. Acute retinal pigment epitheliitis with macular edema. Ann Ophthalmol. 1979 Mar. 11(3):359-61. [Medline].

Luttrull JK, Chittum ME. Acute retinal pigment epitheliitis. Am J Ophthalmol. 1995 Sep. 120(3):389-91. [Medline].

Luttrull JK. Acute retinal pigment epitheliitis. Am J Ophthalmol. 1997 Jan. 123(1):127-9. [Medline].

Baillif S, Wolff B, Paoli V, Gastaud P, Mauget-Faÿsse M. Retinal fluorescein and indocyanine green angiography and spectral-domain optical coherence tomography findings in acute retinal pigment epitheliitis. Retina. 2011 Jun. 31(6):1156-63. [Medline].

Hsu J, Fineman MS, Kaiser RS. Optical coherence tomography findings in acute retinal pigment epitheliitis. Am J Ophthalmol. 2007 Jan. 143(1):163-5. [Medline].

Cho HJ, Lee DW, Kim CG, Kim JW. Spectral domain optical coherence tomography findings in acute retinal pigment epitheliitis. Can J Ophthalmol. 2011 Dec. 46(6):498-500. [Medline].

Bialasiewicz AA, Schonherr U. [Choriocapillaritis (so-called pigment epitheliitis) in Borrelia burgdorferi seroconversion]. Klin Monatsbl Augenheilkd. 1990 Jun. 196(6):481-3. [Medline].

Quillen DA, Zurlo JJ, Cunningham D, Blankenship GW. Acute retinal pigment epitheliitis and hepatitis C. Am J Ophthalmol. 1994 Jul 15. 118(1):120-1. [Medline].

Blanco-Rivera C, Campos-García S. [Acute retinal pigment epitheliitis: a case report]. Arch Soc Esp Oftalmol. 2007 Jul. 82(7):451-3. [Medline].

Piermarocchi S, Corradini R, Midena E, Segato T. Correlation between retinal pigment epitheliitis and central serous chorioretinopathy. Ann Ophthalmol. 1983 May. 15(5):425-8. [Medline].

Gilhotra JS, Gilhotra AK, Holdaway IM, Donaldson ML. Acute retinal pigment epitheliitis associated with intravenous bisphosphonate. Br J Ophthalmol. 2006 Jun. 90(6):798-9. [Medline].

Prost M. Long-term observations of patients with acute retinal pigment epitheliitis. Ophthalmologica. 1989. 199(2-3):84-9. [Medline].

Chittum ME, Kalina RE. Acute retinal pigment epitheliitis. Ophthalmology. 1987 Sep. 94(9):1114-9. [Medline].

Jampol LM, Sieving PA, Pugh D, et al. Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol. 1984 May. 102(5):671-4. [Medline].

Lim JI, Kokame GT, Douglas JP. Multiple evanescent white dot syndrome in older patients. Am J Ophthalmol. 1999 Jun. 127(6):725-8. [Medline].

Fine HF, Spaide RF, Ryan EH Jr, Matsumoto Y, Yannuzzi LA. Acute zonal occult outer retinopathy in patients with multiple evanescent white dot syndrome. Arch Ophthalmol. 2009 Jan. 127(1):66-70. [Medline].

Aaberg TM, Campo RV, Joffe L. Recurrences and bilaterality in the multiple evanescent white-dot syndrome. Am J Ophthalmol. 1985 Jul 15. 100(1):29-37. [Medline].

Asano T, Kondo M, Kondo N, Ueno S, Terasaki H, Miyake Y. High prevalence of myopia in Japanese patients with multiple evanescent white dot syndrome. Jpn J Ophthalmol. 2004 Sep-Oct. 48(5):486-9. [Medline].

Barile GR, Reppucci VS, Schiff WM, Wong DT. Circumpapillary chorioretinopathy in multiple evanescent white-dot syndrome. Retina. 1997. 17(1):75-7. [Medline].

Luttrull JK, Marmor MF, Nanda M. Progressive confluent circumpapillary multiple evanescent white-dot syndrome. Am J Ophthalmol. 1999 Sep. 128(3):378-80. [Medline].

Ray S, Loewenstein J. Atypical manifestation of multiple evanescent white dot syndrome with large peripapillary lesion. Arch Ophthalmol. 2003 Dec. 121(12):1794-6. [Medline].

Yenerel NM, Kucumen B, Gorgun E, Dinc UA. Atypical presentation of multiple evanescent white dot syndrome (MEWDS). Ocul Immunol Inflamm. 2008 May-Jun. 16(3):113-5. [Medline].

Huang J, Spaide R. Appearance of brown areas after resolution of the acute phase of multiple evanescent white dot syndrome. Retina. 2004 Oct. 24(5):814-6. [Medline].

Callanan D, Gass JD. Multifocal choroiditis and choroidal neovascularization associated with the multiple evanescent white dot and acute idiopathic blind spot enlargement syndrome. Ophthalmology. 1992 Nov. 99(11):1678-85. [Medline].

McCollum CJ, Kimble JA. Peripapillary subretinal neovascularization associated with multiple evanescent white-dot syndrome. Arch Ophthalmol. 1992 Jan. 110(1):13-4. [Medline].

Khurana RN, Albini T, Dea MK, Rao NA, Lim JI. Atypical presentation of multiple evanescent white dot syndrome involving granular lesions of varying size. Am J Ophthalmol. 2005 May. 139(5):935-7. [Medline].

Machida S, Fujiwara T, Murai K, Kubo M, Kurosaka D. Idiopathic choroidal neovascularization as an early manifestation of inflammatory chorioretinal diseases. Retina. 2008 May. 28(5):703-10. [Medline].

Papadia M, Herbort CP. Idiopathic choroidal neovascularisation as the inaugural sign of multiple evanescent white dot syndrome. Middle East Afr J Ophthalmol. 2010 Jul. 17(3):270-4. [Medline]. [Full Text].

Furino C, Boscia F, Cardascia N, Alessio G, Sborgia C. Fundus autofluorescence and multiple evanescent white dot syndrome. Retina. 2009 Jan. 29(1):60-3. [Medline].

Dell’Omo R, Mantovani A, Wong R, Konstantopoulou K, Kulwant S, Pavesio CE. Natural evolution of fundus autofluorescence findings in multiple evanescent white dot syndrome: a long-term follow-up. Retina. 2010 Oct. 30(9):1479-87. [Medline].

Penha FM, Navajas EV, Bom Aggio F, Rodrigues EB, Farah ME. Fundus autofluorescence in multiple evanescent white dot syndrome. Case Rep Ophthalmol Med. 2011. 2011:807565. [Medline]. [Full Text].

Li D, Kishi S. Restored photoreceptor outer segment damage in multiple evanescent white dot syndrome. Ophthalmology. 2009 Apr. 116(4):762-70. [Medline].

Ie D, Glaser BM, Murphy RP, et al. Indocyanine green angiography in multiple evanescent white-dot syndrome. Am J Ophthalmol. 1994 Jan 15. 117(1):7-12. [Medline].

Desarnaulds AB, Borruat FX, Herbort CP, de Courten C. [Indocyanine green angiography in “multiple evanescent white dot syndrome” (MEWDS)]. Klin Monatsbl Augenheilkd. 1998 May. 212(5):318-20. [Medline].

Borruat FX, Auer C, Piguet B. Choroidopathy in multiple evanescent white dot syndrome. Arch Ophthalmol. 1995 Dec. 113(12):1569-71. [Medline].

Obana A, Kusumi M, Miki T. Indocyanine green angiographic aspects of multiple evanescent white dot syndrome. Retina. 1996. 16(2):97-104. [Medline].

Tsukamoto E, Yamada T, Kadoi C, Hayasaka S, Nagaki Y, Hayasaka Y. Hypofluorescent spots on indocyanine green angiography at the recovery stage in multiple evanescent white dot syndrome. Ophthalmologica. 1999. 213(5):336-8. [Medline].

Yen MT, Rosenfeld PJ. Persistent indocyanine green angiographic findings in multiple evanescent white dot syndrome. Ophthalmic Surg Lasers. 2001 Mar-Apr. 32(2):156-8. [Medline].

Stanga PE, Lim JI, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology. 2003 Jan. 110(1):15-21; quiz 22-3. [Medline].

Kanis MJ, van Norren D. Integrity of foveal cones in multiple evanescent white dot syndrome assessed with OCT and foveal reflection analyser. Br J Ophthalmol. 2006 Jun. 90(6):795-6. [Medline].

Sikorski BL, Wojtkowski M, Kaluzny JJ, Szkulmowski M, Kowalczyk A. Correlation of spectral optical coherence tomography with fluorescein and indocyanine green angiography in multiple evanescent white dot syndrome. Br J Ophthalmol. 2008 Nov. 92(11):1552-7. [Medline].

Spaide RF, Koizumi H, Freund KB. Photoreceptor outer segment abnormalities as a cause of blind spot enlargement in acute zonal occult outer retinopathy-complex diseases. Am J Ophthalmol. 2008 Jul. 146(1):111-20. [Medline].

Hangai M, Fujimoto M, Yoshimura N. Features and function of multiple evanescent white dot syndrome. Arch Ophthalmol. 2009 Oct. 127(10):1307-13. [Medline].

Silva RA, Albini TA, Flynn HW Jr. Multiple evanescent white dot syndromes. J Ophthalmic Inflamm Infect. 2012 Jun. 2(2):109-11. [Medline]. [Full Text].

Forooghian F, Stetson PF, Gross NE, Meyerle CB. Quantitative assessment of photoreceptor recovery in atypical multiple evanescent white dot syndrome. Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec. 41 Suppl:S77-80. [Medline].

Amin HI. Optical coherence tomography findings in multiple evanescent white dot syndrome. Retina. 2006 Apr. 26(4):483-4. [Medline].

Horiguchi M, Miyake Y, Nakamura M, Fujii Y. Focal electroretinogram and visual field defect in multiple evanescent white dot syndrome. Br J Ophthalmol. 1993 Jul. 77(7):452-5. [Medline].

Yamamoto S, Hayashi M, Tsuruoka M, Yamamoto T, Tsukahara I, Takeuchi S. S-cone electroretinograms in multiple evanescent white dot syndrome. Doc Ophthalmol. 2003 Mar. 106(2):117-20. [Medline].

Chen D, Martidis A, Baumal CR. Transient multifocal electroretinogram dysfunction in multiple evanescent white dot syndrome. Ophthalmic Surg Lasers. 2002 May-Jun. 33(3):246-9. [Medline].

Chen JY, Hood DC, Odel JG, Behrens MM. The effects of retinal abnormalities on the multifocal visual evoked potential. Invest Ophthalmol Vis Sci. 2006 Oct. 47(10):4378-85. [Medline].

Cheng JY, Luu CD, Yeo IY, Chee SP. The outer and inner retinal function in patients with multiple evanescent white dot syndrome. Clin Experiment Ophthalmol. 2009 Jul. 37(5):478-84. [Medline].

Feigl B, Haas A, El-Shabrawi Y. Multifocal ERG in multiple evanescent white dot syndrome. Graefes Arch Clin Exp Ophthalmol. 2002 Aug. 240(8):615-21. [Medline].

Dodwell DG, Jampol LM, Rosenberg M, et al. Optic nerve involvement associated with the multiple evanescent white- dot syndrome. Ophthalmology. 1990 Jul. 97(7):862-8. [Medline].

Hamed LM, Glaser JS, Gass JD, Schatz NJ. Protracted enlargement of the blind spot in multiple evanescent white dot syndrome. Arch Ophthalmol. 1989 Feb. 107(2):194-8. [Medline].

Boscarino MA, Johnson TM. Microperimetry in multiple evanescent white dot syndrome. Can J Ophthalmol. 2007 Oct. 42(5):743-5. [Medline].

Huang HJ, Yamazaki H, Kawabata H, et al. Multifocal electroretinogram in multiple evanescent white dot syndrome. Doc Ophthalmol. 1996-97. 92(4):301-9. [Medline].

Baglivo E, Safran AB, Borruat FX. Multiple evanescent white dot syndrome after hepatitis B vaccine. Am J Ophthalmol. 1996 Sep. 122(3):431-2. [Medline].

Fine L, Fine A, Cunningham ET Jr. Multiple evanescent white dot syndrome following hepatitis a vaccination. Arch Ophthalmol. 2001 Dec. 119(12):1856-8. [Medline].

Stangos A, Zaninetti M, Petropoulos I, Baglivo E, Pournaras C. Multiple evanescent white dot syndrome following simultaneous hepatitis-A and yellow fever vaccination. Ocul Immunol Inflamm. 2006 Oct. 14(5):301-4. [Medline].

Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008 Apr. 30(2):127-34. [Medline].

Schaal S, Schiff WM, Kaplan HJ, Tezel TH. Simultaneous appearance of multiple evanescent white dot syndrome and multifocal choroiditis indicate a common causal relationship. Ocul Immunol Inflamm. 2009 Sep-Oct. 17(5):325-7. [Medline].

Chung YM, Yeh TS, Liu JH. Increased serum IgM and IgG in the multiple evanescent white-dot syndrome. Am J Ophthalmol. 1987 Aug 15. 104(2):187-8. [Medline].

Borruat FX, Herbort CP, Spertini F, Desarnaulds AB. HLA typing in patients with multiple evanescent white dot syndrome (MEWDS). Ocul Immunol Inflamm. 1998 Mar. 6(1):39-41. [Medline].

Bryan RG, Freund KB, Yannuzzi LA, Spaide RF, Huang SJ, Costa DL. Multiple evanescent white dot syndrome in patients with multifocal choroiditis. Retina. 2002 Jun. 22(3):317-22. [Medline].

Shah GK, Kleiner RC, Augsburger JJ, Gill MK, Jampol LM. Primary intraocular lymphoma seen with transient white fundus lesions simulating the multiple evanescent white dot syndrome. Arch Ophthalmol. 2001 Apr. 119(4):617-20. [Medline].

Landolfi M, Bhagat N, Langer P, Rescigno R, Mirani N, Gass JD, et al. Penetrating trauma associated with findings of multiple evanescent white dot syndrome in the second eye: coincidence or an atypical case of sympathetic ophthalmia?. Retina. 2004 Aug. 24(4):637-45. [Medline].

Fahim DK, Bucher R, Johnson MW. The elusive nature of primary intraocular lymphoma. J Neuroophthalmol. 2005 Mar. 25(1):33-6. [Medline].

Tsai L, Jampol LM, Pollock SC, Olk J. Chronic recurrent multiple evanescent white dot syndrome. Retina. 1994. 14(2):160-3. [Medline].

Oh KT, Christmas NJ, Russell SR. Late recurrence and choroidal neovascularization in multiple evanescent white dot syndrome. Retina. 2001. 21(2):182-4. [Medline].

Figueroa MS, Ciancas E, Mompean B, Quereda C. Treatment of multiple evanescent white dot syndrome with cyclosporine. Eur J Ophthalmol. 2001 Jan-Mar. 11(1):86-8. [Medline].

Takahashi Y, Ataka S, Wada S, Kohno T, Nomura Y, Shiraki K. A case of multiple evanescent white dot syndrome treated by steroid pulse therapy. Osaka City Med J. 2006 Dec. 52(2):83-6. [Medline].

Matsumoto Y, Haen SP, Spaide RF. The white dot syndromes. Compr Ophthalmol Update. 2007 Jul-Aug. 8(4):179-200; discussion 203-4. [Medline].

Rouvas AA, Ladas ID, Papakostas TD, Moschos MM, Vergados I. Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to multiple evanescent white dot syndrome. Eur J Ophthalmol. 2007 Nov-Dec. 17(6):996-9. [Medline].

Franceshetti A, Babel J. La choriorétinite en taches de bougie, manifestation de la maladie de Besnier-Boeck. Ophthalmologica. 1949 Oct-Nov. 118(4-5):701-10. [Medline].

Ryan SJ, Maumenee AE. Birdshot retinochoroidopathy. Am J Ophthalmol. 1980 Jan. 89(1):31-45. [Medline].

Gasch AT, Smith JA, Whitcup SM. Birdshot retinochoroidopathy. Br J Ophthalmol. 1999 Feb. 83(2):241-9. [Medline].

Barondes MJ, Fastenberg DM, Schwartz PL, Rosen DA. Peripheral retinal neovascularization in birdshot retinochoroidopathy. Ann Ophthalmol. 1989 Aug. 21(8):306-8. [Medline].

Soubrane G, Coscas G, Binaghi M, Bernard JA. Birdshot retinochoroidopathy and subretinal new vessels. Br J Ophthalmol. 1983 Jul. 67(7):461-7. [Medline].

Giuliari G, Hinkle DM, Foster CS. The spectrum of fundus autofluorescence findings in birdshot chorioretinopathy. J Ophthalmol. 2009. 2009:567693. [Medline]. [Full Text].

Koizumi H, Pozzoni MC, Spaide RF. Fundus autofluorescence in birdshot chorioretinopathy. Ophthalmology. 2008 May. 115(5):e15-20. [Medline].

Guex-Crosier Y, Herbort CP. Prolonged retinal arterio-venous circulation time by fluorescein but not by indocyanine green angiography in birdshot chorioretinopathy. Ocul Immunol Inflamm. 1997 Sep. 5(3):203-6. [Medline].

Fardeau C, Herbort CP, Kullmann N, et al. Indocyanine green angiography in birdshot chorioretinopathy. Ophthalmology. 1999 Oct. 106(10):1928-34. [Medline].

Papadia M, Herbort CP. Indocyanine green angiography (ICGA) is essential for the early diagnosis of birdshot chorioretinopathy. Klin Monbl Augenheilkd. 2012 Apr. 229(4):348-52. [Medline].

Hirose T, Katsumi O, Pruett RC, et al. Retinal function in birdshot retinochoroidopathy. Acta Ophthalmol (Copenh). 1991 Jun. 69(3):327-37. [Medline].

Comander J, Loewenstein J, Sobrin L. Diagnostic testing and disease monitoring in birdshot chorioretinopathy. Semin Ophthalmol. 2011 Jul-Sep. 26(4-5):329-36. [Medline].

de Courten C, Herbort CP. Potential role of computerized visual field testing for the appraisal and follow-up of birdshot chorioretinopathy. Arch Ophthalmol. 1998 Oct. 116(10):1389-91. [Medline].

Giuliari GP, Pujari S, Shaikh M, Marvell D, Foster CS. Microperimetry findings in patients with birdshot chorioretinopathy. Can J Ophthalmol. 2010 Aug. 45(4):399-403. [Medline].

Brézin AP, Monnet D, Cohen JH, Levinson RD. HLA-A29 and birdshot chorioretinopathy. Ocul Immunol Inflamm. 2011 Dec. 19(6):397-400. [Medline].

Nussenblatt RB, Mittal KK, Ryan S, et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol. 1982 Aug. 94(2):147-58. [Medline].

Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol. 1988 Sep. 72(9):646-59. [Medline].

LeHoang PD, Ryan SJ. Birdshot retinochoroidopathy. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. Mosby-Year Book. 1995:570-78.

Kuiper JJ, Mutis T, de Jager W, de Groot-Mijnes JD, Rothova A. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol. 2011 Aug. 152(2):177-182.e1. [Medline].

Miserocchi E, Modorati G, De Benedetto U, Colucci A, Bandello F. Birdshot retinochoroidopathy masquerading as intraocular lymphoma. Ocul Immunol Inflamm. 2012 Aug. 20(4):306-8. [Medline].

Rothova A, Van Schooneveld MJ. The end stage of birdshot retinochoroidopathy. Br J Ophthalmol. 1995 Nov. 79(11):1058-9. [Medline].

Kappel PJ, Monnet D, Yu F, Brezin AP, Levinson RD, Holland GN. Contrast sensitivity among patients with birdshot chorioretinopathy. Am J Ophthalmol. 2009 Feb. 147(2):351-356.e2. [Medline].

Ladas JG, Arnold AC, Holland GN. Control of visual symptoms in two men with birdshot retinochoroidopathy using low-dose oral corticosteroid therapy. Am J Ophthalmol. 1999 Jul. 128(1):116-8. [Medline].

Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye. 1998. 12 (Pt 5):783-8. [Medline].

Rush RB, Goldstein DA, Callanan DG, Meghpara B, Feuer WJ, Davis JL. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol. 2011 Apr. 151(4):630-6. [Medline].

LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm. 2000 Mar. 8(1):49-57. [Medline].

Rothova A, Ossewaarde-van Norel A, Los LI, Berendschot TT. Efficacy of low-dose methotrexate treatment in birdshot chorioretinopathy. Retina. 2011 Jun. 31(6):1150-5. [Medline].

Cervantes-Castañeda RA, Gonzalez-Gonzalez LA, Cordero-Coma M, Yilmaz T, Foster CS. Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up. Br J Ophthalmol. 2013 May. 97(5):637-43. [Medline].

Silverstein BE, Wong IG. Reduction of cyclosporine dosage with ketoconazole in a patient with birdshot retinochoroidopathy. Am J Ophthalmol. 1998 Jan. 125(1):106-8. [Medline].

Nussenblatt RB. Reduction of cyclosporine dosage with ketoconazole in a patient with birdshot retinochoroidopathy. Am J Ophthalmol. 1998 Nov. 126(5):742. [Medline].

Sobrin L, Huang JJ, Christen W, Kafkala C, Choopong P, Foster CS. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol. 2008 Feb. 126(2):186-91. [Medline].

Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd. 2008 May. 225(5):457-61. [Medline].

Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008 Sep. 31(2):91-7. [Medline]. [Full Text].

Jap A, Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol. 2008 Nov. 19(6):535-40. [Medline].

Artornsombudh P, Gevorgyan O, Payal A, Siddique SS, Foster CS. Infliximab Treatment of Patients with Birdshot Retinochoroidopathy. Ophthalmology. 2012 Nov 20. [Medline].

Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the Treatment of Refractory Noninfectious Uveitis: A Study of 88 Patients with Long-term Follow-up. Ophthalmology. 2014 Jan. 121(1):358-64. [Medline].

Junius P. Seltene augenspielgelbider zum klinischen phanomen der retinitis exsuditiva Coats und der retinochoroiditis “parapapillaris”. Arch Augenheilk. 1932. 106:475.

Schatz H, Maumenee AE, Patz A. Geographical helicoid peripapillary choroidopathy: Clinical presentation and fluorescein angiographic findings. Trans Am Acad Ophthalmol Otolaryngol. 1974. 78:747-61.

Hamilton AM, Bird AC. Geographical choroidopathy. Br J Ophthalmol. 1974 Sep. 58(9):784-97. [Medline].

Masi RJ, O”Connor GR, Kimura SJ. Anterior uveitis in geographic or serpiginous choroiditis. Am J Ophthalmol. 1978 Aug. 86(2):228-32. [Medline].

Gass, JDM. Diseases Causing Choroidal Exudative and Hemorrhagic Localized (Disciform) Detachment of the Retina and Retinal Pigment Epithelium. Stereoscopic Atlas of Macular Diseases Diagnosis and Treatment. 4th Ed. St. Louis, MO: Mosby-Year Book Inc.; 1997. Vol 1: 158.

Jumper, J, McDonald, HR, Johnson, RN, et al. Serpiginous Choroiditis. Stephen J Ryan. RETINA. 4th ed. Philadelphia, PA: Elsevier Mosby; 2006. Vol 2: Section 6, Chapter 105, p. 1811.

Abu el-Asrar AM. Serpiginous (geographical) choroiditis. Int Ophthalmol Clin. 1995 Spring. 35(2):87-91. [Medline].

Ciulla TA, Gragoudas ES. Serpiginous choroiditis. Int Ophthalmol Clin. 1996 Winter. 36(1):135-43. [Medline].

Mansour AM, Jampol LM, Packo KH, Hrisomalos NF. Macular serpiginous choroiditis. Retina. 1988. 8(2):125-31. [Medline].

Hardy RA, Schatz H. Macular geographic helicoid choroidopathy. Arch Ophthalmol. 1987 Sep. 105(9):1237-42. [Medline].

Sahu DK, Rawoof A, Sujatha B. Macular serpiginous choroiditis. Indian J Ophthalmol. 2002 Sep. 50(3):189-96. [Medline].

Chisholm IH, Gass JD, Hutton WL. The late stage of serpiginous (geographic) choroiditis. Am J Ophthalmol. 1976 Sep. 82(3):343-51. [Medline].

Jampol LM, Orth D, Daily MJ, Rabb MF. Subretinal neovascularization with geographic (serpiginous) choroiditis. Am J Ophthalmol. 1979 Oct. 88(4):683-9. [Medline].

Blumenkranz MS, Gass JD, Clarkson JG. Atypical serpiginous choroiditis. Arch Ophthalmol. 1982 Nov. 100(11):1773-5. [Medline].

Laatikainen L, Erkkila H. Subretinal and disc neovascularisation in serpiginous choroiditis. Br J Ophthalmol. 1982 May. 66(5):326-31. [Medline].

Friberg TR. Serpiginous choroiditis with branch vein occlusion and bilateral periphlebitis. Case report. Arch Ophthalmol. 1988 May. 106(5):585-6. [Medline].

Steinmetz RL, Fitzke FW, Bird AC. Treatment of cystoid macular edema with acetazolamide in a patient with serpiginous choroidopathy. Retina. 1991. 11(4):412-5. [Medline].

Gregory ME, Bhatt U, Benskin S, Banerjee S. Bilateral full thickness macular holes in association with serpiginous choroiditis. Ocul Immunol Inflamm. 2009 Sep-Oct. 17(5):328-9. [Medline].

Tang J, Fillmore G, Nussenblatt RB. Antiphospholipid antibody syndrome mimicking serpiginous choroidopathy. Ocul Immunol Inflamm. 2009 Jul-Aug. 17(4):278-81. [Medline].

Fung AT, Nicolò M, Yzer S, Traverso CE, Yannuzzi LA. Eales disease associated with serpiginous choroiditis. Arch Ophthalmol. 2012 Nov. 130(11):1484-6. [Medline].

Gass, JDM. Diseases Causing Choroidal Exudative and Hemorrhagic Localized (Disciform) Detachment of the Retina and Retinal Pigment Epithelium. Stereoscopic Atlas of Macular Diseases Diagnosis and Treatment. 4th Ed. St. Louis, MO: Mosby-Year Book, Inc.; 1997. Vol 1: 160.

Gupta A, Biswas J. Serpiginous choroiditis and acute retinal necrosis occurring in the same patient. Indian J Ophthalmol. 2013 Jun. 61(6):303-4. [Medline]. [Full Text].

Carreño E, Portero A, Herreras JM, López MI. Assesment of fundus autofluorescence in serpiginous and serpiginous-like choroidopathy. Eye (Lond). 2012 Sep. 26(9):1232-6. [Medline]. [Full Text].

Cardillo Piccolino F, Grosso A, Savini E. Fundus autofluorescence in serpiginous choroiditis. Graefes Arch Clin Exp Ophthalmol. 2009 Feb. 247(2):179-85. [Medline].

Yeh S, Forooghian F, Wong WT, Faia LJ, Cukras C, Lew JC, et al. Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol. 2010 Jan. 128(1):46-56. [Medline]. [Full Text].

Agrawal RV, Biswas J, Gunasekaran D. Indocyanine green angiography in posterior uveitis. Indian J Ophthalmol. 2013 Apr. 61(4):148-59. [Medline]. [Full Text].

Giovannini A, Mariotti C, Ripa E, Scassellati-Sforzolini B. Indocyanine green angiographic findings in serpiginous choroidopathy. Br J Ophthalmol. 1996 Jun. 80(6):536-40. [Medline]. [Full Text].

Giovannini A, Ripa E, Scassellati-Sforzolini B, Ciardella A, Tom D, Yannuzzi L. Indocyanine green angiography in serpiginous choroidopathy. Eur J Ophthalmol. 1996 Jul-Sep. 6(3):299-306. [Medline].

van Velthoven ME, Ongkosuwito JV, Verbraak FD, Schlingemann RO, de Smet MD. Combined en-face optical coherence tomography and confocal ophthalmoscopy findings in active multifocal and serpiginous chorioretinitis. Am J Ophthalmol. 2006 May. 141(5):972-5. [Medline].

Gallagher MJ, Yilmaz T, Cervantes-Castañeda RA, Foster CS. The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol. 2007 Dec. 91(12):1680-5. [Medline]. [Full Text].

Arantes TE, Matos K, Garcia CR, Silva TG, Sabrosa AS, Muccioli C. Fundus autofluorescence and spectral domain optical coherence tomography in recurrent serpiginous choroiditis: case report. Ocul Immunol Inflamm. 2011 Feb. 19(1):39-41. [Medline].

Punjabi OS, Rich R, Davis JL, Gregori G, Flynn HW Jr, Lujan BJ, et al. Imaging serpiginous choroidopathy with spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2008 Jul-Aug. 39(4 Suppl):S95-8. [Medline].

Chisholm IH, Gass JD, Hutton WL. The late stage of serpiginous (geographic) choroiditis. Am J Ophthalmol. 1976 Sep. 82(3):343-51. [Medline].

Pilotto E, Vujosevic S, Grgic VA, Sportiello P, Convento E, Secchi AG, et al. Retinal function in patients with serpiginous choroiditis: a microperimetry study. Graefes Arch Clin Exp Ophthalmol. 2010 Sep. 248(9):1331-7. [Medline].

Wu JS, Lewis H, Fine SL, et al. Clinicopathologic findings in a patient with serpiginous choroiditis and treated choroidal neovascularization. Retina. 1989. 9(4):292-301. [Medline].

Edelsten C, Stanford MR, Graham EM. Serpiginous choroiditis: an unusual presentation of ocular sarcoidosis. Br J Ophthalmol. 1994 Jan. 78(1):70-1. [Medline].

Richardson RR, Cooper IS, Smith JL. Serpiginous choroiditis and unilateral extrapyramidal dystonia. Ann Ophthalmol. 1981 Jan. 13(1):15-9. [Medline].

King DG, Grizzard WS, Sever RJ, Espinoza L. Serpiginous choroidopathy associated with elevated factor VIII-von Willebrand factor antigen. Retina. 1990. 10(2):97-101. [Medline].

Christmas NJ, Oh KT, Oh DM, Folk JC. Long-term follow-up of patients with serpinginous choroiditis. Retina. 2002 Oct. 22(5):550-6. [Medline].

Akpek EK, Baltatzis S, Yang J, Foster CS. Long-term immunosuppressive treatment of serpiginous choroiditis. Ocul Immunol Inflamm. 2001 Sep. 9(3):153-67. [Medline].

Akpek EK, Ilhan-Sarac O. New treatments for serpiginous choroiditis. Curr Opin Ophthalmol. 2003 Jun. 14(3):128-31. [Medline].

Markomichelakis NN, Halkiadakis I, Papaeythymiou-Orchan S, Giannakopoulos N, Ekonomopoulos N, Kouris T. Intravenous pulse methylprednisolone therapy for acute treatment of serpiginous choroiditis. Ocul Immunol Inflamm. 2006 Feb. 14(1):29-33. [Medline].

[Guideline] Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct. 130(4):492-513. [Medline].

Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991 Jun. 98(6):944-51; discussion 951-2. [Medline].

Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology. 2002 Aug. 109(8):1506-13. [Medline].

Wadhwa N, Garg SP, Mehrotra A. Prospective evaluation of intravitreal triamcinolone acetonide in serpiginous choroiditis. Ophthalmologica. 2010. 224(3):183-7. [Medline].

Adigüzel U, Sari A, Ozmen C, Oz O. Intravitreal triamcinolone acetonide treatment for serpiginous choroiditis. Ocul Immunol Inflamm. 2006 Dec. 14(6):375-8. [Medline].

Karacorlu S, Ozdemir H, Karacorlu M. Intravitreal triamcinolone acetonide in serpiginous choroiditis. Jpn J Ophthalmol. 2006 May-Jun. 50(3):290-1. [Medline].

Pathengay A. Intravitreal triamcinolone acetonide in serpiginous choroidopathy. Indian J Ophthalmol. 2005 Mar. 53(1):77-9. [Medline].

Seth RK, Gaudio PA. Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. Ocul Immunol Inflamm. 2008 May-Jun. 16(3):103-5. [Medline].

Sahin OG. Long-Term Cyclophosphamide Treatment in a Case with Serpiginous Choroiditis. Case Rep Ophthalmol. 2010 Oct 5. 1(2):71-76. [Medline]. [Full Text].

Seve P, Mennesson E, Grange JD, Broussolle C, Kodjikian L. Infliximab in serpiginous choroiditis. Acta Ophthalmol. 2010 Dec. 88(8):e342-3. [Medline].

Llorenç V, Molins B, Rey A, Mesquida M, Adán A. Adalimumab in serpiginous choroiditis. Ocul Immunol Inflamm. 2013 Jun. 21(3):237-40. [Medline].

[Guideline] Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology. 2013 Dec 17. [Medline].

Mansour AM, Arevalo JF, Fardeau C, Hrisomalos EN, Chan WM, Lai TY, et al. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol. 2012 Jun. 47(3):269-74. [Medline].

Julián K, Terrada C, Fardeau C, Cassoux N, Français C, LeHoang P, et al. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Ophthalmol. 2011 Mar. 89(2):179-84. [Medline].

Balaskas K, Ur Rehman S, D’Souza Y. Long-term ranibizumab treatment for choroidal neovascularization secondary to serpiginous choroiditis. Can J Ophthalmol. 2012 Oct. 47(5):e15-7. [Medline].

Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011 May. 31(5):871-9. [Medline].

Song MH, Roh YJ. Intravitreal ranibizumab for choroidal neovascularisation in serpiginous choroiditis. Eye (Lond). 2009 Sep. 23(9):1873-5. [Medline].

Barbazetto IA, Lesser RL, Tom D, Freund KB. Diffuse unilateral subacute neuroretinitis masquerading as a white-dot syndrome. Br J Ophthalmol. 2009 May. 93(5):574-6, 655. [Medline].

Goldberg MA, Kazacos KR, Boyce WM, et al. Diffuse unilateral subacute neuroretinitis. Morphometric, serologic, and epidemiologic support for Baylisascaris as a causative agent. Ophthalmology. 1993 Nov. 100(11):1695-701. [Medline].

de Souza EC, Nakashima Y. Diffuse unilateral subacute neuroretinitis. Report of transvitreal surgical removal of a subretinal nematode. Ophthalmology. 1995 Aug. 102(8):1183-6. [Medline].

Cohen SM. Multiple Evanescent White Dot Syndrome After Vaccination for Human Papilloma Virus and Meningococcus. J Pediatr Ophthalmol Strabismus. 2009 Jun 25. [Medline].

Gross NE, Yannuzzi LA, Freund KB, Spaide RF, Amato GP, Sigal R. Multiple evanescent white dot syndrome. Arch Ophthalmol. 2006 Apr. 124(4):493-500. [Medline].

Kiss S, Anzaar F, Stephen Foster C. Birdshot retinochoroidopathy. Int Ophthalmol Clin. 2006 Spring. 46(2):39-55. [Medline].

Levinson RD, Brezin A, Rothova A, Accorinti M, Holland GN. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol. 2006 Jan. 141(1):185-7. [Medline].

Lim L, Harper A, Guymer R. Choroidal lesions preceding symptom onset in birdshot chorioretinopathy. Arch Ophthalmol. 2006 Jul. 124(7):1057-8. [Medline].

Monnet D, Brézin AP. Birdshot chorioretinopathy. Curr Opin Ophthalmol. 2006 Dec. 17(6):545-50. [Medline].

Monnet D, Brézin AP, Holland GN, Yu F, Mahr A, Gordon LK, et al. Longitudinal cohort study of patients with birdshot chorioretinopathy. I. Baseline clinical characteristics. Am J Ophthalmol. 2006 Jan. 141(1):135-42. [Medline].

Nazari Khanamiri H, Rao NA. Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis. Surv Ophthalmol. 2013 May-Jun. 58(3):203-32. [Medline]. [Full Text].

Nguyen MH, Witkin AJ, Reichel E, Ko TH, Fujimoto JG, Schuman JS, et al. Microstructural abnormalities in MEWDS demonstrated by ultrahigh resolution optical coherence tomography. Retina. 2007 Apr-May. 27(4):414-8. [Medline].

Postelmans L, Pasteels B, Coquelet P, et al. Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like). Ocul Immunol Inflamm. 2005 Sep-Oct. 13(5):361-6. [Medline].

Shah KH, Levinson RD, Yu F, Goldhardt R, Gordon LK, Gonzales CR, et al. Birdshot chorioretinopathy. Surv Ophthalmol. 2005 Nov-Dec. 50(6):519-41. [Medline].

Tellier Z. Human immunoglobulins in intraocular inflammation. Ann N Y Acad Sci. 2007 Sep. 1110:337-47. [Medline].

Vasconcelos-Santos DV, Rao PK, Davies JB, Sohn EH, Rao NA. Clinical features of tuberculous serpiginouslike choroiditis in contrast to classic serpiginous choroiditis. Arch Ophthalmol. 2010 Jul. 128(7):853-8. [Medline].

Yang DS, Hilford DJ, Conrad D. Acute posterior multifocal placoid pigment epitheliopathy after meningococcal C conjugate vaccine. Clin Experiment Ophthalmol. 2005 Apr. 33(2):219-21. [Medline].

Sam E Mansour, MD, MSc, FACS, FRCSC Clinical Professor of Ophthalmology, George Washington University School of Medicine; Medical Director, The Virginia Retina Center

Sam E Mansour, MD, MSc, FACS, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Medical Association, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, California Medical Association, Canadian Medical Association, College of Physicians and Surgeons of Ontario, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Iridex Corp.; Alcon ; Allergan Inc.; Diopsys Inc.; Genentech; Alimera Sciences<br/>Serve(d) as a speaker or a member of a speakers bureau for: Iridex Corp.; Diopsys Inc.; Alimera Sciences<br/>Received research grant from: Iridex Corp.; Alcon ; Allergan Inc.; Diopsys Inc.; Genentech; Alimera Sciences.

Gary R Cook, MD, FACS Associate Physician, Virginia Retina Center, LLC

Gary R Cook, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Retina Specialists

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Steve Charles, MD Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Brian A Phillpotts, MD, MD 

Brian A Phillpotts, MD, MD is a member of the following medical societies: American Academy of Ophthalmology, American Diabetes Association, American Medical Association, National Medical Association

Disclosure: Nothing to disclose.

Multifocal Choroidopathy Syndromes

Research & References of Multifocal Choroidopathy Syndromes|A&C Accounting And Tax Services
Source